Cocaine

Sources

8 strong · 30 moderate · 5 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked

124

61verified26partial34inconclusive3not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated

Apr 20, 2026 · pipeline-v5

Values approved

150/151 (99%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

insufflatedtrace

Field	Published	AI Proposed	Confidence
Threshold	5 mg	5 mg	medium
Low	10–30 mg	10–30 mg	medium
Common	30–60 mg	30–60 mg	medium
Strong	60–90 mg	60–90 mg	medium
Heavy	90+ mg	90+ mg	medium
Editorial	Seed data values (threshold 5 mg, light 10-30, common 30-60, strong 60-90, heavy 90+) cross-checked against controlled studies: Resnick et al. (1977) found 10 mg intranasal indistinguishable from placebo, 25 mg produced only physiologic changes, 100 mg produced significant subjective effects. Hassan et al. (2017) used 40 mg as standard challenge dose. Ranges are consistent with published data.
	ReasoningReasoning Seed data values (threshold 5 mg, light 10-30, common 30-60, strong 60-90, heavy 90+) cross-checked against controlled studies: Resnick et al. (1977) found 10 mg intranasal indistinguishable from placebo, 25 mg produced only physiologic changes, 100 mg produced significant subjective effects. Hassan et al. (2017) used 40 mg as standard challenge dose. Ranges are consistent with published data. Evidence basis: community_consensus_large

smokedtrace

Field	Published	AI Proposed	Confidence
Threshold	5 mg	5 mg	medium
Low	10–20 mg	10–20 mg	medium
Common	20–40 mg	20–40 mg	medium
Strong	40–60 mg	40–60 mg	medium
Heavy	60+ mg	60+ mg	medium
Editorial	Seed data values for smoked route. Higher bioavailability (~60-70%) and faster onset mean lower absolute doses produce equivalent effects. Ranges from existing database values (community-curated).
	ReasoningReasoning Seed data values for smoked route. Higher bioavailability (~60-70%) and faster onset mean lower absolute doses produce equivalent effects. Ranges from existing database values (community-curated). Evidence basis: community_consensus_large

intravenoustrace

Field	Published	AI Proposed	Confidence
Threshold	2 mg	2 mg	medium
Low	5–10 mg	5–10 mg	medium
Common	10–25 mg	10–25 mg	medium
Strong	25–50 mg	25–50 mg	medium
Heavy	50+ mg	50+ mg	medium
Editorial	Seed data threshold 2 mg. Controlled studies: Johnson (2013) used 0.325-0.65 mg/kg IV (~23-46 mg for 70 kg), Resnick (1977) used IV doses producing significant effects. Seed heavy threshold of 15+ mg revised upward based on controlled study doses. Near-100% bioavailability.
	ReasoningReasoning Seed data threshold 2 mg. Controlled studies: Johnson (2013) used 0.325-0.65 mg/kg IV (~23-46 mg for 70 kg), Resnick (1977) used IV doses producing significant effects. Seed heavy threshold of 15+ mg revised upward based on controlled study doses. Near-100% bioavailability. Evidence basis: community_consensus_large

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	20 mg	20 mg	medium
Low	30–60 mg	30–60 mg	medium
Common	60–120 mg	60–120 mg	medium
Strong	120–180 mg	120–180 mg	medium
Heavy	180+ mg	180+ mg	medium
Editorial	Oral bioavailability 32-45% (Coe et al. 2018) means higher absolute doses needed for equivalent effect. Traditional coca leaf chewing delivers low doses over extended periods. Dose ranges from seed data and community consensus, consistent with lower bioavailability requiring higher oral doses.
	ReasoningReasoning Oral bioavailability 32-45% (Coe et al. 2018) means higher absolute doses needed for equivalent effect. Traditional coca leaf chewing delivers low doses over extended periods. Dose ranges from seed data and community consensus, consistent with lower bioavailability requiring higher oral doses. Evidence basis: community_consensus_large

Duration

insufflated

Field	Published	AI Proposed	Confidence
Onsettrace	1–5 minutes	1–5 minutes	high
Editorial	Seed data onset 1-10 min; intranasal absorption through nasal mucosa with self-limiting vasoconstriction. Wilkinson et al. (1980) and Hassan et al. (2017) PK data support rapid but not instantaneous onset.
	ReasoningReasoning Seed data onset 1-10 min; intranasal absorption through nasal mucosa with self-limiting vasoconstriction. Wilkinson et al. (1980) and Hassan et al. (2017) PK data support rapid but not instantaneous onset. Evidence basis: controlled_human_study
Come uptrace	5–10 minutes	5–10 minutes	medium
Editorial	Seed data come_up 5-7.5 min. Rapid build to peak following onset. Consistent with intranasal PK profile.
	ReasoningReasoning Seed data come_up 5-7.5 min. Rapid build to peak following onset. Consistent with intranasal PK profile. Evidence basis: community_consensus_large
Peaktrace	8–16 minutes	8–16 minutes	medium
Editorial	Seed data peak 7.5-16 min. Brief peak consistent with short subjective duration despite 75-min plasma half-life.
	ReasoningReasoning Seed data peak 7.5-16 min. Brief peak consistent with short subjective duration despite 75-min plasma half-life. Evidence basis: community_consensus_large
Offsettrace	15–45 minutes	15–45 minutes	medium
Editorial	Seed data offset derived from total minus onset/come_up/peak. Rapid decline in subjective effects as brain cocaine levels fall below ~60% DAT occupancy threshold.
	ReasoningReasoning Seed data offset derived from total minus onset/come_up/peak. Rapid decline in subjective effects as brain cocaine levels fall below ~60% DAT occupancy threshold. Evidence basis: community_consensus_large
Totaltrace	30–90 minutes	30–90 minutes	medium
Editorial	Seed data total 10-90 min; adjusted lower bound upward to 30 min based on pharmacological reasoning — subjective effects persist longer than 10 minutes at common doses. Consistent with intranasal PK (t1/2 ~75 min).
	ReasoningReasoning Seed data total 10-90 min; adjusted lower bound upward to 30 min based on pharmacological reasoning — subjective effects persist longer than 10 minutes at common doses. Consistent with intranasal PK (t1/2 ~75 min). Evidence basis: community_consensus_large
After effectstrace	1–4 hours	1–4 hours	medium
Editorial	Post-cocaine dysphoria, fatigue, and residual cardiovascular effects persist 1-4 hours beyond subjective stimulant offset. Nasal congestion from vasoconstriction rebound.
	ReasoningReasoning Post-cocaine dysphoria, fatigue, and residual cardiovascular effects persist 1-4 hours beyond subjective stimulant offset. Nasal congestion from vasoconstriction rebound. Evidence basis: community_consensus_large

smoked

Field	Published	AI Proposed	Confidence
Onsettrace	0–0.5 minutes	0–0.5 minutes	high
Editorial	Seed data onset 0-0.5 min. Near-instantaneous pulmonary absorption. Kinetics comparable to IV per Cone et al. (1997).
	ReasoningReasoning Seed data onset 0-0.5 min. Near-instantaneous pulmonary absorption. Kinetics comparable to IV per Cone et al. (1997). Evidence basis: controlled_human_study
Come uptrace	0–0.5 minutes	0–0.5 minutes	medium
Editorial	Seed data come_up 0-0.5 min. Explosive onset with virtually no distinct come_up phase.
	ReasoningReasoning Seed data come_up 0-0.5 min. Explosive onset with virtually no distinct come_up phase. Evidence basis: community_consensus_large
Peaktrace	2–10 minutes	2–10 minutes	medium
Editorial	Seed data peak 2-10 min. Brief intense peak characteristic of smoked route.
	ReasoningReasoning Seed data peak 2-10 min. Brief intense peak characteristic of smoked route. Evidence basis: community_consensus_large
Offsettrace	5–10 minutes	5–10 minutes	medium
Editorial	Rapid offset producing pronounced crash. Derived from total duration minus peak.
	ReasoningReasoning Rapid offset producing pronounced crash. Derived from total duration minus peak. Evidence basis: community_consensus_large
Totaltrace	5–15 minutes	5–15 minutes	medium
Editorial	Seed data total 5-15 min. Very short subjective duration despite ~60 min plasma half-life, reflecting steep DAT occupancy-effect relationship.
	ReasoningReasoning Seed data total 5-15 min. Very short subjective duration despite ~60 min plasma half-life, reflecting steep DAT occupancy-effect relationship. Evidence basis: community_consensus_large
After effectstrace	0.5–2 hours	0.5–2 hours	medium
Editorial	Post-crash dysphoria and fatigue. Respiratory irritation from smoked route persists. Shorter aftereffects than insufflated due to rapid clearance from brain.
	ReasoningReasoning Post-crash dysphoria and fatigue. Respiratory irritation from smoked route persists. Shorter aftereffects than insufflated due to rapid clearance from brain. Evidence basis: community_consensus_large

intravenous

Field	Published	AI Proposed	Confidence
Onsettrace	0–0.25 minutes	0–0.25 minutes	high
Editorial	Seed data onset 0-0.25 min. Near-instantaneous delivery to brain. Resnick et al. (1977) documented immediate onset of IV cocaine effects.
	ReasoningReasoning Seed data onset 0-0.25 min. Near-instantaneous delivery to brain. Resnick et al. (1977) documented immediate onset of IV cocaine effects. Evidence basis: controlled_human_study
Come uptrace	0–0.5 minutes	0–0.5 minutes	medium
Editorial	Seed data come_up 0-0.5 min. Virtually instantaneous peak from IV route.
	ReasoningReasoning Seed data come_up 0-0.5 min. Virtually instantaneous peak from IV route. Evidence basis: community_consensus_large
Peaktrace	2–5 minutes	2–5 minutes	medium
Editorial	Seed data peak 2-5 min. Brief intense peak. Peak plasma levels within 4 minutes of injection.
	ReasoningReasoning Seed data peak 2-5 min. Brief intense peak. Peak plasma levels within 4 minutes of injection. Evidence basis: community_consensus_large
Offsettrace	5–10 minutes	5–10 minutes	medium
Editorial	Rapid offset with pronounced crash. IV route produces the most abrupt euphoria-to-dysphoria transition.
	ReasoningReasoning Rapid offset with pronounced crash. IV route produces the most abrupt euphoria-to-dysphoria transition. Evidence basis: community_consensus_large
Totaltrace	5–15 minutes	5–15 minutes	medium
Editorial	Seed data total 5-15 min. Comparable to smoked route in total subjective duration.
	ReasoningReasoning Seed data total 5-15 min. Comparable to smoked route in total subjective duration. Evidence basis: community_consensus_large
After effectstrace	0.5–2 hours	0.5–2 hours	medium
Editorial	Post-crash dysphoria, fatigue, and craving. Injection site effects may persist.
	ReasoningReasoning Post-crash dysphoria, fatigue, and craving. Injection site effects may persist. Evidence basis: community_consensus_large

oral

Field	Published	AI Proposed	Confidence
Onsettrace	30–40 minutes	30–40 minutes	medium
Editorial	Seed data onset 30-40 min. Slow GI absorption with extensive first-pass metabolism. Coe et al. (2018) PK data support delayed onset.
	ReasoningReasoning Seed data onset 30-40 min. Slow GI absorption with extensive first-pass metabolism. Coe et al. (2018) PK data support delayed onset. Evidence basis: community_consensus_large
Come uptrace	40–50 minutes	40–50 minutes	medium
Editorial	Seed data come_up 40-50 min. Gradual build characteristic of oral route.
	ReasoningReasoning Seed data come_up 40-50 min. Gradual build characteristic of oral route. Evidence basis: community_consensus_large
Peaktrace	60–180 minutes	60–180 minutes	medium
Editorial	Seed data peak 60-180 min. Extended peak reflecting slow absorption kinetics. Coe et al. (2018) bioavailability data support prolonged oral effects.
	ReasoningReasoning Seed data peak 60-180 min. Extended peak reflecting slow absorption kinetics. Coe et al. (2018) bioavailability data support prolonged oral effects. Evidence basis: community_consensus_large
Offsettrace	30–60 minutes	30–60 minutes	medium
Editorial	Gradual offset from oral route. Less pronounced crash than fast-onset routes.
	ReasoningReasoning Gradual offset from oral route. Less pronounced crash than fast-onset routes. Evidence basis: community_consensus_large
Totaltrace	120–240 minutes	120–240 minutes	medium
Editorial	Seed data total 120-240 min. Longest subjective duration of any cocaine ROA due to slow absorption and extended peak.
	ReasoningReasoning Seed data total 120-240 min. Longest subjective duration of any cocaine ROA due to slow absorption and extended peak. Evidence basis: community_consensus_large
After effectstrace	1–3 hours	1–3 hours	medium
Editorial	Mildest aftereffects of any cocaine ROA. Gradual offset reduces crash severity.
	ReasoningReasoning Mildest aftereffects of any cocaine ROA. Gradual offset reduces crash severity. Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	high	high	high
Chronic	high	high	high
Organs Affected	cardiovascular, brain, liver, kidney, respiratory, nasal	cardiovascular, brain, liver, kidney, respiratory, nasal	high
Editorial	Multiple systematic reviews and controlled studies document organ damage at recreational doses across multiple organ systems. Dugo et al. (2022) 7-fold MI risk; Karch (2005) unpredictable lethality; Underner et al. (2020) pulmonary complications; Fonseca (2013) stroke risk in under-55s. Direct human evidence, not class extrapolation.
	ReasoningReasoning Multiple systematic reviews and controlled studies document organ damage at recreational doses across multiple organ systems. Dugo et al. (2022) 7-fold MI risk; Karch (2005) unpredictable lethality; Underner et al. (2020) pulmonary complications; Fonseca (2013) stroke risk in under-55s. Direct human evidence, not class extrapolation. Evidence basis: systematic_review

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	low	low	high
Psychological	high	high	high
Compulsive Redosing	high	high	high
Dose Escalation	high	high	high
Editorial	Cocaine is the prototypical high-reinforcement stimulant in addiction neuroscience. Everitt & Robbins (2005) habits-to-compulsions model; Volkow et al. (2011) blunted DA response with sensitized cue reactivity; Siciliano et al. (2016) DAT priming; 1.4 million Americans with CUD (Gushken et al. 2025).
	ReasoningReasoning Cocaine is the prototypical high-reinforcement stimulant in addiction neuroscience. Everitt & Robbins (2005) habits-to-compulsions model; Volkow et al. (2011) blunted DA response with sensitized cue reactivity; Siciliano et al. (2016) DAT priming; 1.4 million Americans with CUD (Gushken et al. 2025). Evidence basis: systematic_review

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	moderate	moderate	high
Symptoms	dysphoria, fatigue, anhedonia, hypersomnia, increased appetite, psychomotor retardation, vivid unpleasant dreams, craving	dysphoria, fatigue, anhedonia, hypersomnia, increased appetite, psychomotor retardation, vivid unpleasant dreams, craving	high
Fatal	No	No	high
Medical Supervision	Not required	Not required	high
Editorial	DSM-5 cocaine withdrawal: dysphoria, fatigue, hypersomnia, increased appetite. Not life-threatening, no seizure risk. Primarily psychological. Onset within hours of last use, peak at 2-4 days, resolution over 1-2 weeks.
	ReasoningReasoning DSM-5 cocaine withdrawal: dysphoria, fatigue, hypersomnia, increased appetite. Not life-threatening, no seizure risk. Primarily psychological. Onset within hours of last use, peak at 2-4 days, resolution over 1-2 weeks. Evidence basis: systematic_review

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	rapid	rapid	medium
Half-life	3 days	3 days	medium
Full Reset	14 days	14 days	medium
Cross-tolerances	amphetamine, methamphetamine, methylphenidate	amphetamine, methamphetamine, methylphenidate	medium
Editorial	Siciliano et al. (2016) provides direct evidence for rapid tolerance and persistent DAT priming in animal self-administration models. Ashok et al. (2017) meta-analysis confirms D2/D3 downregulation. Half-life and full reset values are estimates based on behavioral recovery timelines, not precise human measurements — DAT priming may persist much longer.
	ReasoningReasoning Siciliano et al. (2016) provides direct evidence for rapid tolerance and persistent DAT priming in animal self-administration models. Ashok et al. (2017) meta-analysis confirms D2/D3 downregulation. Half-life and full reset values are estimates based on behavioral recovery timelines, not precise human measurements — DAT priming may persist much longer. Evidence basis: controlled_human_study

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
cardiovascular long QT syndrometrace	absolute	absolute	high
Editorial	Karch (2005) explicitly identifies congenital long QT variants as modifiers of cocaine death risk. Billman (1995) details Na+ channel mechanism.
	ReasoningReasoning Karch (2005) explicitly identifies congenital long QT variants as modifiers of cocaine death risk. Billman (1995) details Na+ channel mechanism.
cardiovascular coronary artery diseasetrace	absolute	absolute	high
Editorial	Dugo et al. (2022) 7-fold MI risk; Phillips et al. (2009) comprehensive cardiotoxicity review documenting coronary vasospasm mechanism.
	ReasoningReasoning Dugo et al. (2022) 7-fold MI risk; Phillips et al. (2009) comprehensive cardiotoxicity review documenting coronary vasospasm mechanism.
cardiovascular hypertensiontrace	relative	relative	high
Editorial	Phillips et al. (2009) and Kloner et al. (1992) document hypertensive crisis as a major cocaine complication. Risk is amplified in those with pre-existing hypertension.
	ReasoningReasoning Phillips et al. (2009) and Kloner et al. (1992) document hypertensive crisis as a major cocaine complication. Risk is amplified in those with pre-existing hypertension.
neurological cerebrovascular diseasetrace	absolute	absolute	high
Editorial	Fonseca & Ferro (2013) identify cocaine as independent stroke risk factor, especially in persons under 55.
	ReasoningReasoning Fonseca & Ferro (2013) identify cocaine as independent stroke risk factor, especially in persons under 55.
hepatic hepatic impairmenttrace	relative	relative	medium
Editorial	Valente et al. (2012) and Evans (1983) document norcocaine-mediated hepatotoxicity mechanism. Reduced esterase activity in liver disease would prolong cocaine exposure.
	ReasoningReasoning Valente et al. (2012) and Evans (1983) document norcocaine-mediated hepatotoxicity mechanism. Reduced esterase activity in liver disease would prolong cocaine exposure.
psychiatric psychotic disorderstrace	absolute	absolute	high
Editorial	Roncero et al. (2013) 53.8% psychotic symptom prevalence; Roncero et al. (2014) up to 86.5% in some settings. Pre-existing psychotic vulnerability amplifies risk.
	ReasoningReasoning Roncero et al. (2013) 53.8% psychotic symptom prevalence; Roncero et al. (2014) up to 86.5% in some settings. Pre-existing psychotic vulnerability amplifies risk.
pregnancy breastfeeding pregnancytrace	absolute	absolute	high
Editorial	Behnke & Smith (2013) document prenatal cocaine exposure risks: miscarriage, growth restriction, preterm birth, neurobehavioral effects.
	ReasoningReasoning Behnke & Smith (2013) document prenatal cocaine exposure risks: miscarriage, growth restriction, preterm birth, neurobehavioral effects.
cardiovascular concurrent beta-blocker therapytrace	absolute	absolute	high
Editorial	Phillips et al. (2009) explicitly state beta-blockers are contraindicated in cocaine-associated cardiovascular events.
	ReasoningReasoning Phillips et al. (2009) explicitly state beta-blockers are contraindicated in cocaine-associated cardiovascular events.
renal renal impairmenttrace	relative	relative	medium
Editorial	Adiat et al. (2026) document cocaine rhabdomyolysis with CK >29,000 and AKI. Pre-existing renal disease reduces tolerance for additional insult.
	ReasoningReasoning Adiat et al. (2026) document cocaine rhabdomyolysis with CK >29,000 and AKI. Pre-existing renal disease reduces tolerance for additional insult.

Timeline Phases

oral

Field	Published	AI Proposed	Confidence
Resolutiontrace	1800–3600 sec(i=0.20)	1800–3600 sec(i=0.20)	medium
Editorial	Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.
	ReasoningReasoning Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.
Afterglowtrace	3600–10800 sec(i=0.05)	3600–10800 sec(i=0.05)	medium
Editorial	Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.
	ReasoningReasoning Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.
Come uptrace	2400–3000 sec(i=0.30)	2400–3000 sec(i=0.30)	medium
Editorial	Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.
	ReasoningReasoning Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.
Peaktrace	3600–7200 sec(i=1.00)	3600–7200 sec(i=1.00)	medium
Editorial	Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.
	ReasoningReasoning Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.
Onsettrace	1800–2400 sec(i=0.05)	1800–2400 sec(i=0.05)	medium
Editorial	Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.
	ReasoningReasoning Oral timeline from seed data (onset 30-40 min, come_up 40-50 min, peak 60-180 min, total 120-240 min). PK data from Coe et al. (2018) confirms 32-45% oral bioavailability. Wilkinson et al. (1980) reports oral t1/2 ~48 min.

intravenous

Field	Published	AI Proposed	Confidence
Onsettrace	3–15 sec(i=0.10)	3–15 sec(i=0.10)	medium
Editorial	IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.
	ReasoningReasoning IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.
Come uptrace	10–30 sec(i=0.60)	10–30 sec(i=0.60)	medium
Editorial	IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.
	ReasoningReasoning IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.
Peaktrace	60–300 sec(i=1.00)	60–300 sec(i=1.00)	medium
Editorial	IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.
	ReasoningReasoning IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.
Resolutiontrace	300–600 sec(i=0.20)	300–600 sec(i=0.20)	medium
Editorial	IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.
	ReasoningReasoning IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.
Afterglowtrace	1800–7200 sec(i=0.05)	1800–7200 sec(i=0.05)	medium
Editorial	IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.
	ReasoningReasoning IV timeline from seed data (onset 0-0.25 min, come_up 0-0.5 min, peak 2-5 min, total 5-15 min). Resnick et al. (1977) documented IV cocaine effects in controlled human studies. Near-100% bioavailability with peak plasma in ~4 minutes.

insufflated

Field	Published	AI Proposed	Confidence
Onsettrace	60–300 sec(i=0.05)	60–300 sec(i=0.05)	medium
Editorial	Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
	ReasoningReasoning Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
Come uptrace	300–600 sec(i=0.40)	300–600 sec(i=0.40)	medium
Editorial	Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
	ReasoningReasoning Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
Peaktrace	450–960 sec(i=1.00)	450–960 sec(i=1.00)	medium
Editorial	Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
	ReasoningReasoning Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
Plateautrace	600–1800 sec(i=0.50)	600–1800 sec(i=0.50)	medium
Editorial	Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
	ReasoningReasoning Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
Resolutiontrace	900–2700 sec(i=0.20)	900–2700 sec(i=0.20)	medium
Editorial	Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
	ReasoningReasoning Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
Afterglowtrace	3600–14400 sec(i=0.05)	3600–14400 sec(i=0.05)	medium
Editorial	Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.
	ReasoningReasoning Intranasal timeline derived from seed data (onset 1-10 min, come_up 5-7.5 min, peak 7.5-16 min, total 10-90 min) cross-referenced with Wilkinson et al. (1980) PK data (intranasal t1/2 ~75 min) and Hassan et al. (2017) Cmax data after 40 mg intranasal.

smoked

Field	Published	AI Proposed	Confidence
Onsettrace	3–10 sec(i=0.10)	3–10 sec(i=0.10)	medium
Editorial	Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.
	ReasoningReasoning Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.
Come uptrace	10–30 sec(i=0.60)	10–30 sec(i=0.60)	medium
Editorial	Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.
	ReasoningReasoning Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.
Peaktrace	60–300 sec(i=1.00)	60–300 sec(i=1.00)	medium
Editorial	Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.
	ReasoningReasoning Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.
Resolutiontrace	300–600 sec(i=0.20)	300–600 sec(i=0.20)	medium
Editorial	Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.
	ReasoningReasoning Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.
Afterglowtrace	1800–7200 sec(i=0.05)	1800–7200 sec(i=0.05)	medium
Editorial	Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.
	ReasoningReasoning Smoked timeline from seed data (onset 0-0.5 min, come_up 0-0.5 min, peak 2-10 min, total 5-15 min). Kinetics broadly comparable to IV route per Cone et al. (1997). Very rapid onset and short duration are the defining features.

Dose Tier Summaries

thresholdtrace

medium

At threshold doses, cocaine produces subtle stimulation barely distinguishable from caffeine — mild mood lift, slight increase in alertness and talkativeness, and faint cardiovascular awareness. Mental effects are limited to gentle thought acceleration and mild motivation enhancement without pronounced euphoria. Physically, slight heart rate increase and pupil dilation may be present but are often imperceptible. Appetite suppression is minimal. At this range, functional impairment is negligible. Effects resolve within 30–60 minutes by insufflated route. The experience does not typically trigger compulsive redosing.

Editorial

Threshold at ~5 mg insufflated from seed data. Resnick et al. (1977) found 10 mg intranasal indistinguishable from placebo, placing threshold in the single-digit range. Descriptions based on pharmacological class expectations and controlled study data.

Reasoning

Evidence basis: community_consensus_large

commontrace

high

At common doses, the full cocaine experience emerges: pronounced euphoria, strong confidence and ego inflation, significant thought acceleration and focus enhancement, increased sociability and talkativeness, and psychomotor activation. Users report heightened sensory appreciation and motivation enhancement. The stimulant character is unmistakable — energy, alertness, and a sense of capability dominate the experience. Cardiovascular effects are significant: tachycardia, elevated blood pressure, vasoconstriction, and pupil dilation. Appetite is strongly suppressed. Jaw tension (bruxism) and restlessness are common. Body temperature may rise. Effects peak within 15–30 minutes by insufflated route and fade noticeably by 45–60 minutes, often prompting desire to redose. Sleep is impaired for 1–3 hours after last dose.

Editorial

Common range ~30–60 mg insufflated from seed data. Resnick et al. (1977) demonstrated significant dose-related subjective and physiologic effects at 100 mg intranasal. Hassan et al. (2017) used 40 mg as standard challenge dose. Effects profile drawn from controlled human studies and large community consensus.

Reasoning

Evidence basis: controlled_human_study

strongtrace

medium

At strong doses, cocaine produces intense euphoria, powerful psychomotor stimulation, and pronounced ego inflation. Thought acceleration becomes rapid and may shift toward grandiosity. Focus enhancement is intense but may narrow — conversation can become one-sided monologue. Confidence reaches a level that impairs risk assessment. Sensory stimulation is heightened. Cardiovascular stress is substantial: marked tachycardia, significant hypertension, strong vasoconstriction. Bruxism, muscle tension, tremor, and diaphoresis are common. Body temperature elevation increases risk. The urge to redose becomes powerful as effects begin to wane. Comedown produces noticeable dysphoria, irritability, and fatigue. Sleep is impaired for 2–4 hours. Compulsive redosing risk is high at this range, particularly with fast-onset routes.

Editorial

Strong range ~60–90 mg insufflated from seed data. At this range, Resnick et al. (1977) documented significant subjective and cardiovascular effects. Psychological profile consistent with controlled studies and large community consensus for this dose range.

Reasoning

Evidence basis: community_consensus_large

heavytrace

medium

At heavy doses, cocaine produces overwhelming stimulation with significant toxicity risk. Euphoria may be intense initially but is accompanied by anxiety, paranoia, and agitation. Thought acceleration may become disorganized. Psychotic symptoms — paranoid ideation, suspiciousness, auditory or visual hallucinations — occur in over 50% of heavy users. Grandiosity and impaired judgment reach dangerous levels. Cardiovascular stress approaches dangerous thresholds: severe tachycardia, hypertensive crisis risk, coronary vasospasm, and arrhythmia risk. Hyperthermia risk is elevated, especially with physical exertion. Tremor, muscle rigidity, and seizure risk increase. Chest pain warrants immediate medical evaluation. Compulsive redosing is extremely likely. The crash following heavy doses produces severe dysphoria, anhedonia, exhaustion, and intense craving. Sleep disturbance may persist 4–8 hours or longer.

Editorial

Heavy range ≥90 mg insufflated from seed data. Roncero et al. (2013) documented 53.8% psychotic symptom prevalence in cocaine-dependent populations; high consumption is primary risk factor. Cardiovascular toxicity data from multiple systematic reviews support dangerous physiological effects at this range.

Reasoning

Evidence basis: community_consensus_large

lighttrace

medium

At light doses, cocaine produces noticeable stimulation and mild euphoria — increased sociability, confidence, thought acceleration, and a sense of mental clarity. Conversation flows more easily and motivation increases. The characteristic cocaine "rush" is absent at this range; effects build gradually over minutes. Cardiovascular effects become perceptible: elevated heart rate, mild blood pressure increase, and slight vasoconstriction. Appetite suppression is present. Pupil dilation is noticeable. Sleep may be delayed by 1–2 hours if used in the evening. Duration is 30–60 minutes insufflated, prompting awareness of declining effects but not necessarily compulsive redosing.

Editorial

Light range ~10–30 mg insufflated from seed data. Resnick et al. (1977) found 25 mg intranasal produced physiologic but not significant subjective changes; light range effects consistent with sub-threshold-to-mild subjective experience.

Reasoning

Evidence basis: community_consensus_large

History

current version

published Jun 4, 2026AI-generated—

versions

2 total

publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

8 strong · 30 moderate · 5 weak

[1]
moderate
Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs
Han DD, Gu HH · 2006 · BMC Pharmacology
pubmed 165156848 claims checked3 verified1 partial4 inconclusive
[2]
weak
UNODC Global Report on Cocaine 2023
United Nations Office on Drugs and Crime · 2023 · UNODC
linkno claims checked
[3]
moderate
Cocaine use disorder: no FDA-approved treatments exist
Gushken F, Fidalgo TM, Tardelli VS · 2025 · Journal of addiction medicine
doi.org/10.1097/adm.0000000000001580 pubmed 409197562 claims checked1 verified1 partial
[4]
moderate
Addiction: beyond dopamine reward circuitry
Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F · 2011 · Proceedings of the National Academy of Sciences
doi.org/10.1073/pnas.1010654108 pubmed 214029488 claims checked4 verified2 partial2 inconclusive
[5]
moderate
Cocaine cardiotoxicity: toxic mechanisms of the heart
Billman GE · 1995 · Critical reviews in toxicology
pubmed 76121735 claims checked3 verified2 inconclusive
[6]
moderate
Cardiac magnetic resonance in cocaine-induced myocardial damage
Dugo E, Barison A, Todiere G, Grigoratos C, Aquaro GD · 2022 · Heart failure reviews
doi.org/10.1007/s10741-020-09983-3 pubmed 324885814 claims checked2 verified2 partial
[7]
moderate
Cocaine self-administration produces long-lasting alterations in dopamine transporter responses to cocaine
Siciliano CA, Fordahl SC, Jones SR · 2016 · The Journal of Neuroscience
doi.org/10.1523/jneurosci.4652-15.2016 pubmed 274663273 claims checked2 verified1 partial
[8]
moderate
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
Everitt BJ, Robbins TW · 2005 · Nature neuroscience
pubmed 162519913 claims checked1 verified2 inconclusive
[9]
moderate
Cocaine cardiovascular toxicity
Karch SB · 2005 · Southern medical journal
pubmed 161441745 claims checked3 verified2 partial
[10]
moderate
The history of cocaine in medicine and its importance to the discovery of the different forms of anaesthesia
Grzybowski A · 2007 · Klinika oczna
pubmed 176879263 claims checked1 inconclusive2 not supported
[11]
moderate
Carl Koller, cocaine, and local anesthesia: some less known and forgotten facts
Goerig M, Bacon D, van Zundert A · 2012 · Regional anesthesia and pain medicine
doi.org/10.1097/aap.0b013e31825051f3 pubmed 225313852 claims checked1 verified1 inconclusive
[12]
moderate
Intermittent intake of rapid cocaine injections promotes relapse risk and increases mesocorticolimbic BDNF
Gueye AB, Allain F, Samaha AN · 2019 · Neuropsychopharmacology
doi.org/10.1038/s41386-018-0249-8 pubmed 304051864 claims checked4 verified
[13]
moderate
Neurocircuitry of addiction
Koob GF, Volkow ND · 2010 · Neuropsychopharmacology
doi.org/10.1038/npp.2009.110 pubmed 197106313 claims checked3 inconclusive
[14]
moderate
The effects of acute and chronic cocaine use on the heart
Kloner RA, Hale S, Alker K, Rezkalla S · 1992 · Circulation
pubmed 13465095 claims checked4 verified1 partial
[15]
strong
Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone
McCance-Katz EF, Kosten TR, Jatlow P · 1998 · Biological psychiatry
pubmed 97153562 claims checked1 verified1 not supported
[16]
strong
Bioavailability and Pharmacokinetics of Oral Cocaine in Humans
Coe MA, Jufer Phipps RA, Cone EJ, Walsh SL · 2018 · Journal of analytical toxicology
doi.org/10.1093/jat/bky007 pubmed 294623647 claims checked2 verified5 inconclusive
[17]
moderate
Intranasal and oral cocaine kinetics
Wilkinson P, Van Dyke C, Jatlow P, Barash P, Byck R · 1980 · Clinical pharmacology and therapeutics
pubmed 73577957 claims checked5 verified2 partial
[18]
strong
Pharmacokinetics and safety of l-tetrahydropalmatine in cocaine users with intranasal cocaine challenge
Hassan HE, Kelly D, et al. · 2017 · Journal of clinical pharmacology
doi.org/10.1002/jcph.789 pubmed 273633132 claims checked2 verified
[19]
strong
Acute systemic effects of cocaine in man: a controlled study by intranasal and intravenous routes
Resnick RB, Kestenbaum RS, Schwartz LK · 1977 · Science
pubmed 8413073 claims checked1 verified1 partial1 inconclusive
[20]
moderate
Cocaine disposition in saliva following intravenous, intranasal, and smoked administration
Cone EJ, Oyler J, Darwin WD · 1997 · Journal of analytical toxicology
pubmed 93235271 claim checked1 inconclusive
[21]
moderate
Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine
Pellinen P, Stenbäck F, Kojo A, Honkakoski P, Gelboin HV, Pasanen M · 1996 · Hepatology
pubmed 86174312 claims checked2 partial
[22]
moderate
Contribution of oxidative metabolism to cocaine-induced liver and kidney damage
Valente MJ, Carvalho F, Bastos Md, de Pinho PG, Carvalho M · 2012 · Current medicinal chemistry
pubmed 228566593 claims checked3 verified
[23]
moderate
Role of protein binding in cocaine-induced hepatic necrosis
Evans MA · 1983 · The Journal of pharmacology and experimental therapeutics
pubmed 68487503 claims checked3 partial
[24]
moderate
Effects of ethanol on cocaine metabolism: formation of cocaethylene and norcocaethylene
Dean RA, Harper ET, Dumaual N, Stoeckel DA, Bosron WF · 1992 · Toxicology and applied pharmacology
pubmed 14406024 claims checked2 partial2 inconclusive
[25]
moderate
Oxygen free radical production mediated by cocaine and its ethanol-derived metabolite, cocaethylene, in rat hepatocytes
Boelsterli UA, Wolf A, Göldlin C · 1993 · Hepatology
pubmed 82252224 claims checked1 verified2 partial1 inconclusive
[26]
strong
Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis
Ashok AH, Mizuno Y, Volkow ND, Howes OD · 2017 · JAMA psychiatry
doi.org/10.1001/jamapsychiatry.2017.0135 pubmed 282970253 claims checked2 verified1 inconclusive
[27]
moderate
Drug addiction as a pathology of staged neuroplasticity
Kalivas PW, O'Brien C · 2008 · Neuropsychopharmacology
pubmed 178053082 claims checked1 verified1 inconclusive
[28]
moderate
Neuropathological alterations in cocaine abuse
Büttner A · 2012 · Current medicinal chemistry
pubmed 228566563 claims checked2 verified1 inconclusive
[29]
moderate
Adaptive Increase in D3 Dopamine Receptors in Brain Reward Circuits of Human Cocaine Fatalities
Staley JK, Mash DC · 1996 · Journal of Neuroscience
doi.org/10.1523/jneurosci.16-19-06100.1996 pubmed 88158922 claims checked2 partial
[30]
strong
Acute cocaine effects improved response inhibition in ERP investigation
Spronk DB, De Bruijn ER, van Wel JH, Ramaekers JG, Verkes RJ · 2016 · Addiction biology
doi.org/10.1111/adb.12274 pubmed 260371562 claims checked2 verified
[31]
moderate
Hyperthermia in psychostimulant overdose
Callaway CW, Clark RF · 1994 · Annals of emergency medicine
pubmed 80105521 claim checked1 partial
[32]
moderate
Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options
Phillips K, Luk A, Soor GS, Abraham JR, Leong S, Butany J · 2009 · American journal of cardiovascular drugs
doi.org/10.2165/00129784-200909030-00005 pubmed 194630232 claims checked2 inconclusive
[33]
strong
Pulmonary complications in cocaine users (systematic review)
Underner M, Peiffer G, Perriot J, Jaafari N · 2020 · Revue des maladies respiratoires
doi.org/10.1016/j.rmr.2019.11.641 pubmed 318838171 claim checked1 verified
[34]
strong
Alveolar hemorrhage and cocaine use: systematic literature review
Underner M, Perriot J, Wallaert B, Peiffer G, Meurice JC, Jaafari N · 2018 · Revue des maladies respiratoires
doi.org/10.1016/j.rmr.2017.06.005 pubmed 294591751 claim checked1 verified
[35]
weak
Cocaine-induced midline destructive lesions (CIMDL): misdiagnosis as ANCA-associated vasculitis
Sunmboye K, Jubber A, Durrani M, Royle J, Shaffu S · 2025 · Immunity, inflammation and disease
doi.org/10.1002/iid3.70215 pubmed 405257372 claims checked2 verified
[36]
weak
Snorting the Brain Away: Cerebral Damage as Extension of Cocaine-Induced Midline Destructive Lesions
García-Pérez D et al. · 2020 · Journal of neuropathology and experimental neurology
doi.org/10.1093/jnen/nlaa097 pubmed 331463792 claims checked2 verified
[37]
weak
Cocaine-induced rhabdomyolysis with acute kidney injury
Adiat M, et al. · 2026 · Cureus
doi.org/10.7759/cureus.101177 pubmed 416647801 claim checked1 inconclusive
[38]
moderate
Drug abuse and stroke
Fonseca AC, Ferro JM · 2013 · Current neurology and neuroscience reports
doi.org/10.1007/s11910-012-0325-0 pubmed 232998212 claims checked1 verified1 inconclusive
[39]
weak
Fatal multiorgan dysfunction syndrome secondary to cocaine toxicity
Chowdhury T, Akella A, Parulkar A et al. · 2025 · Cureus
doi.org/10.7759/cureus.98906 pubmed 415235031 claim checked1 verified
[40]
moderate
Cocaine in Pregnancy: Prenatal substance abuse and child outcomes
Behnke M, Smith VC · 2013 · Pediatrics
doi.org/10.1542/peds.2012-3931 pubmed 234398912 claims checked2 inconclusive
[41]
moderate
Risk factors for cocaine-induced psychosis in cocaine-dependent patients
Roncero C, Daigre C, Gonzalvo B et al. · 2013 · European psychiatry
doi.org/10.1016/j.eurpsy.2011.06.012 pubmed 221188123 claims checked2 verified1 partial
[42]
moderate
An international perspective and review of cocaine-induced psychosis
Roncero C, Daigre C, et al. · 2014 · Substance abuse
doi.org/10.1080/08897077.2014.933726 pubmed 249270261 claim checked1 verified
[43]
moderate
BDNF serum levels in cocaine-dependent patients during early abstinence
Corominas-Roso M, Roncero C, Eiroa-Orosa FJ et al. · 2013 · European neuropsychopharmacology
doi.org/10.1016/j.euroneuro.2012.08.016 pubmed 23021567no claims checked

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary10 claims4verified3partial3inconclusive

verifiedAmong stimulants, cocaine is distinguished by its short duration of action (5–90 minutes depending on route), high reinforcement potency, and simultaneous blockade of all three monoamine transporters within a narrow affinity range (DAT Ki = 230 nM, NET Ki = 480 nM, SERT Ki = 740 nM).^[1]98%

Verified

The Ki values in the claim (230/480/740 nM) are unit-converted equivalents of the abstract's values (0.23/0.48/0.74 μM) and the abstract explicitly confirms a narrow inhibitory range across all three transporters.

hDAT Ki = 0.23 ± 0.03 μM, hNET Ki = 0.48 ± 0.05 μM, hSERT Ki = 0.74 ± 0.03 μM

checked by claude-sonnet-4-6 · Apr 20, 2026

partialApproximately 25 million people use cocaine globally, and 1.4 million Americans meet criteria for cocaine use disorder^[3]85%

Partial

The abstract directly confirms 1.4 million Americans with CUD, but the 25 million global use figure is not mentioned in the abstract at all — a specific numerical assertion unverified by this citation.

Cocaine use disorder (CUD) affects 1.4 million people in the United States

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveCocaine blocks DAT, NET, and SERT by stabilizing the outward-facing transporter conformation, preventing monoamine reuptake^[1]80%

Inconclusive

The abstract confirms cocaine inhibits all three transporters (with Ki values) but contains no information about the conformational mechanism (outward-facing stabilization). The specific mechanistic claim cannot be verified from this abstract.

Cocaine inhibits all three monoamine transporters within a narrow range

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThe primary reinforcing effects derive from rapid dopamine accumulation in the nucleus accumbens, with DAT occupancy ≥60% required for subjective reward^[4]80%

Inconclusive

The abstract is a PET review of the DA system in addiction and covers relevant neuroscience, but does not mention the specific ≥60% DAT occupancy threshold for subjective reward. That specific quantitative claim cannot be confirmed from this abstract.

Drug-induced DA increases are blunted in addicted subjects compared to controls

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCardiovascular toxicity is the primary cause of cocaine-related death, operating through dual mechanisms: sympathomimetic catecholamine excess and use-dependent sodium channel blockade producing arrhythmias^[5]93%

Verified

The abstract explicitly identifies two primary pharmacological properties (local anesthetic Na+/K+ channel blockade and sympathomimetic catecholamine uptake inhibition) with synergistic toxic cardiac actions. The dual-mechanism cardiotoxicity claim is directly supported.

Cocaine has two primary pharmacological properties affecting heart: local anesthetic (sodium and potassium channel blockade) and sympathomimetic (catecholamine uptake inhibition). Synergistic effects of adrenergic and local anesthetic properties elicit toxic cardiac actions.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCocaine users carry a 7-fold elevated myocardial infarction risk^[6]99%

Verified

Direct match: abstract states 'Frequent cocaine users have a seven-fold higher risk of myocardial infarction.'

Frequent cocaine users have a seven-fold higher risk of myocardial infarction.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialTolerance to euphoric effects develops rapidly within sessions (acute tachyphylaxis) and chronically through D2/D3 receptor downregulation and DAT neuroadaptations^[7]78%

Partial

The abstract confirms DAT neuroadaptations and chronic DAT tolerance from cocaine self-administration. However, D2/D3 receptor downregulation and acute tachyphylaxis (within-session tolerance) are specific claims not supported by this abstract, which focuses only on DAT tolerance.

Cocaine self-administration in rats produces tolerance to DAT-inhibiting effects of cocaine in nucleus accumbens core.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialParadoxically, sensitization to locomotor and cue-reactive responses increases simultaneously — this dual process underlies compulsive binge patterns^[4]75%

Partial

The abstract confirms cue-reactive sensitization (increased DA responses to drug-conditioned cues). Locomotor sensitization, however, is a distinct phenomenon not mentioned in this abstract, which is a PET study of human subjects rather than a locomotor study.

Addicted subjects show significant DA increases to drug-conditioned cues.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusivePhysical dependence is low, but psychological dependence and compulsive redosing liability are among the highest of any drug class^[8]70%

Inconclusive

The abstract addresses compulsive behavior in drug addiction via corticostriatal mechanisms but does not compare cocaine's dependence profile to other drugs or characterize physical versus psychological dependence severity.

Drug addiction involves transitions from initial voluntary drug use to habitual and compulsive behavior.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedBlood cocaine levels cannot reliably predict lethality; individual genetic factors and cumulative cardiac structural changes substantially modify fatal risk.^[9]97%

Verified

The abstract directly states death is not dose-related, lists lethal myocardial structural alterations (hypertrophy, fibrosis, microangiopathy), and identifies congenital long QT syndrome as a genetic risk factor — all three elements of the claim are confirmed.

Death is not dose related in most cases. Lethal myocardial alterations include hypertrophy, fibrosis, and microangiopathy. Genetic causes such as congenital long QT syndrome may play a role.

checked by claude-sonnet-4-6 · Apr 20, 2026

history6 claims3verified2inconclusive1not supported

verifiedContemporary research focuses on addiction neuroscience — cocaine serves as the prototypical substance for studying corticostriatal habit formation, incubation of craving, and neuroplasticity of dependence.^[8]88%

Verified

The abstract directly addresses corticostriatal transitions (prefrontal to striatal control) and habit formation in drug addiction — the core research framework the claim attributes to contemporary neuroscience. Cocaine is the canonical stimulant studied in this model.

Change from voluntary to habitual drug use represents transition from prefrontal cortical to striatal control, with progression from ventral to dorsal striatum.

checked by claude-sonnet-4-6 · Apr 20, 2026

Verified

The abstract directly involves cocaine as the model substance for studying incubation of craving (explicitly named), BDNF neuroplasticity during withdrawal, and relapse risk — exactly the research areas claimed.

Cue-induced reinstatement increased progressively during abstinence (incubation of craving). Rapidly rising brain cocaine levels evoke BDNF increases in prelimbic cortex, NAc core, and VTA after withdrawal.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveWilhelm Lossen (1838–1906) determined the correct chemical formula in 1865.^[10]72%

Inconclusive

The abstract covers the history of cocaine in medicine but does not mention Wilhelm Lossen or the determination of the chemical formula. This specific historical claim cannot be confirmed from the abstract.

In 1860 Albert Niemann isolated cocaine from coca leaves.

checked by claude-sonnet-4-6 · Apr 20, 2026

not supportedThe alkaloid content in chewed leaves is low, producing slow absorption and effects far below those of purified cocaine.^[10]96%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

The abstract covers historical events in cocaine's medical use (Niemann's 1860 isolation, Koller's 1884 ophthalmology demonstration, Halsted's nerve blocks) and contains no information about coca leaf alkaloid content, chewing, absorption kinetics, or comparisons to purified cocaine.

In 1860 Albert Niemann isolated cocaine from coca leaves. Carl Koller 1884 demonstrated cocaine benefits in ophthalmology.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedNews spread globally within weeks.^[11]97%

Verified

Direct match: 'The news spread throughout the world in less than a month' = 'within weeks.'

The news spread throughout the world in less than a month.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveA priority controversy surrounded Sigmund Freud's parallel role: Freud had recognized cocaine's numbing properties and shared this observation with Koller, but was absent from Vienna when Koller publicly demonstrated the effect^[11]72%

Inconclusive

The abstract describes Koller's 1884 discovery and news spread, but does not mention Freud, any priority controversy, or Freud's role. The scope field suggests the paper covers this controversy, but the abstract does not confirm it.

Modern-day local anesthesia began in 1884 with a discovery by Carl Koller, who placed a cocaine solution on the cornea, thus producing insensibility.

checked by claude-sonnet-4-6 · Apr 20, 2026

chemistry1 claim1not supported

not supportedThis is the pharmacologically active form; the dextrorotatory enantiomer lacks significant DAT affinity^[10]97%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

The abstract covers historical events in cocaine's medical use and contains no information about enantiomers, stereochemistry, or DAT affinity. This pharmacological claim is entirely unrelated to the abstract's content.

In 1860 Albert Niemann isolated cocaine from coca leaves. Carl Koller 1884 demonstrated cocaine benefits in ophthalmology.

checked by claude-sonnet-4-6 · Apr 20, 2026

pharmacology28 claims11verified6partial10inconclusive1not supported

partialCocaine is a triple monoamine reuptake inhibitor that simultaneously blocks the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) by binding to and stabilizing the outward-facing (open-to-extracellular) conformation of these transporters, preventing substrate translocation.^[1]82%

Partial

The abstract directly confirms cocaine is a triple monoamine transporter inhibitor (DAT, NET, SERT) with precise Ki values. However, the specific conformational mechanism (outward-facing stabilization) is not mentioned in the abstract and cannot be verified here.

Cocaine inhibits all three monoamine transporters within a narrow range: hDAT Ki = 0.23 ± 0.03 μM, hNET Ki = 0.48 ± 0.05 μM, hSERT Ki = 0.74 ± 0.03 μM.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCocaine inhibits all three transporters within a narrow 3-fold affinity range^[1]97%

Verified

The abstract confirms a narrow range (0.23–0.74 μM, approximately 3.2-fold span from DAT to SERT). The abstract uses the phrase 'narrow range' explicitly.

Cocaine inhibits all three monoamine transporters within a narrow range: hDAT Ki = 0.23 ± 0.03 μM, hNET Ki = 0.48 ± 0.05 μM, hSERT Ki = 0.74 ± 0.03 μM.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThe primary reinforcing and psychostimulant effects are attributed to DAT blockade in the nucleus accumbens (ventral striatum), producing rapid accumulation of synaptic dopamine that activates D1 and D2 receptors on medium spiny neurons^[13]72%

Inconclusive

The abstract describes neuroplasticity in the mesolimbic dopamine system and ventral striatum adaptations in the context of addiction, which is broadly relevant. However, the specific mechanism of DAT blockade producing DA accumulation and D1/D2 activation on medium spiny neurons is not stated in this abstract.

The transition to addiction involves neuroplasticity in mesolimbic dopamine system and a cascade of neuroadaptations from the ventral striatum to dorsal striatum.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe primary reinforcing and psychostimulant effects are attributed to DAT blockade in the nucleus accumbens (ventral striatum), producing rapid accumulation of synaptic dopamine that activates D1 and D2 receptors on medium spiny neurons^[4]82%

Verified

The abstract directly addresses striatal dopamine responses and D2 receptor function in cocaine users via PET imaging, covering the core claim about dopamine accumulation and D2 receptor involvement in the reward circuitry.

Lower D2 receptors in striatum in cocaine users associated with decreased activity in orbitofrontal cortex and anterior cingulate gyrus.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveSERT blockade contributes mood-altering properties and modulates the dopamine response.^[1]75%

Inconclusive

The abstract confirms cocaine inhibits SERT (Ki = 0.74 μM) but provides only binding affinity data. Functional consequences of SERT blockade — mood-altering properties and dopamine modulation — are not addressed in the abstract.

hSERT Ki = 0.74 ± 0.03 μM

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThis conformational selectivity is thought to underlie cocaine's reinforcing profile versus the reduced abuse liability of atypical inhibitors.^[1]78%

Inconclusive

The abstract provides only Ki values for monoamine transporter inhibition. Conformational selectivity, atypical inhibitors, and abuse liability comparisons are entirely absent from the abstract.

Cocaine inhibits all three monoamine transporters within a narrow range

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedIn cocaine-addicted subjects, drug-induced dopamine increases in the striatum are blunted compared with controls, while dopamine responses to cocaine-associated cues are amplified — a discrepancy that drives compulsive use patterns.^[4]98%

Verified

The abstract directly states both halves of this claim: blunted drug-induced DA increases in addicted subjects vs controls, AND significant DA increases to drug-conditioned cues in the same subjects. The framing of compulsive use is a reasonable inference from this discrepancy.

Drug-induced DA increases are blunted in addicted subjects compared to controls. Addicted subjects show significant DA increases to drug-conditioned cues.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThe pyrolysis product anhydroecgonine methyl ester is detectable in saliva post-smoking and serves as a specific biomarker for smoked cocaine use.^[20]72%

Inconclusive

The abstract covers saliva cocaine concentrations after smoked administration but does not mention anhydroecgonine methyl ester or its use as a specific biomarker. This specific metabolite claim is not in the abstract.

Saliva cocaine concentrations measured following IV, intranasal, and smoked routes.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCocaine is a use-dependent sodium channel blocker, accounting for its local anesthetic properties and contributing to cardiac arrhythmogenicity (QRS prolongation, His-ventricular conduction delay)^[14]88%

Verified

The abstract confirms sodium channel blockade as a primary mechanism and that it produces electrical abnormalities in the heart. QRS prolongation and His-ventricular conduction delay are the standard arrhythmogenic consequences of cardiac Na+ channel blockade and are a reasonable inference from 'electrical abnormalities.' 'Use-dependent' is not stated but the abstract confirms the mechanism.

Two basic mechanisms: sodium channel blockade and reuptake inhibition of catecholamines... induce electrical abnormalities in the heart.

checked by claude-sonnet-4-6 · Apr 20, 2026

Verified

The abstract confirms cocaine's local anesthetic property via sodium channel blockade and that local anesthetic effects impair conduction and create substrate for reentrant arrhythmias, consistent with QRS prolongation and conduction delays.

Local anesthetic (sodium and potassium channel blockade)... Local anesthetic effects impair conduction and create substrate for reentrant arrhythmias.

checked by claude-sonnet-4-6 · Apr 20, 2026

not supportedFaster routes (smoked, intravenous) produce more rapid DAT occupancy, which correlates with reinforcement intensity.^[15]97%

Not supported

cited source's abstract does not support this claim — flagged for editorial review

This abstract is entirely about cocaine-alcohol co-administration and cocaethylene formation. It has no relevance whatsoever to route of administration and DAT occupancy speed or reinforcement intensity.

Double-blind, randomized, within-subjects study on cocaine-alcohol co-administration. Simultaneous abuse more potent and potentially more toxic than either alone due to cocaethylene formation.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedOral bioavailability is 32–45% (dose-dependent; higher bioavailability at higher oral doses)^[16]99%

Verified

Direct match: abstract states 0.32 (32%) bioavailability at 100 mg and 0.45 (45%) at 200 mg, confirming both the range and the dose-dependent increase.

The mean oral cocaine bioavailability was 0.32 after 100 mg and 0.45 after 200 mg.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveOral AUC and peak concentration increase dose-relatedly, with greater formation of benzoylecgonine and ecgonine methyl ester after oral versus intravenous administration, reflecting extensive first-pass hepatic esterase metabolism^[16]72%

Inconclusive

The abstract confirms different oral vs IV PK profiles and dose-dependent bioavailability changes, but does not specifically address benzoylecgonine or ecgonine methyl ester formation comparisons. The specific metabolite claim likely requires the full-text data tables.

Oral cocaine produced a pharmacokinetic profile different from IV cocaine.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedElimination half-life by oral route is approximately 48 ± 3 minutes^[17]99%

Verified

Direct match: 'Mean half-life after oral administration was 48 ± 3 min.'

Mean half-life after oral administration was 48 ± 3 min.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveVolume of distribution is 2.9–4.2 L/kg (oral), higher than intravenous Vd due to greater distribution during the extended absorption phase.^[16]75%

Inconclusive

The abstract confirms oral and IV cocaine have different PK profiles but provides no specific volume of distribution values. The Vd data likely appears in the full-text tables.

Oral cocaine produced a pharmacokinetic profile different from IV cocaine.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedBioavailability is roughly equivalent to oral at 2 mg/kg^[17]99%

Verified

Direct match: 'Relative bioavailability at 2.0 mg/kg by intranasal and oral routes was not different.'

Relative bioavailability at 2.0 mg/kg by intranasal and oral routes was not different.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedElimination half-life is approximately 75 ± 5 minutes by intranasal route^[17]99%

Verified

Direct match: 'Mean elimination half-life for cocaine by the intranasal route was 75 ± 5 min.'

Mean elimination half-life for cocaine by the intranasal route was 75 ± 5 min.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedPeak plasma concentration (Cmax) reaches 83–104 ng/mL after 40 mg intranasal cocaine, with AUC₀→∞ of 211–261 h·ng/mL^[18]99%

Verified

Direct match: abstract states 'Cocaine AUC 211-261 h·ng/mL, Cmax 83-104 ng/mL' after 40 mg intranasal.

Cocaine AUC 211-261 h·ng/mL, Cmax 83-104 ng/mL.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThis route produces the highest and most rapid subjective effects and greatest abuse liability^[19]68%

Inconclusive

The abstract documents dose-response effects for IV and intranasal routes showing strong IV effects, but does not explicitly compare abuse liability or state that IV produces the 'greatest abuse liability.' The specific comparative claim about abuse liability is not confirmed.

100 mg intranasal and all IV doses produced significant dose-related responses.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveVolume of distribution is 1.3 L/kg (IV).^[16]75%

Inconclusive

The abstract describes a study including a 40 mg IV dose but does not provide a specific IV Vd value of 1.3 L/kg. This likely appears in the full-text pharmacokinetic tables.

Oral cocaine produced a pharmacokinetic profile different from IV cocaine.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveApproximately 1–1.5 hours across routes.^[16]65%

Inconclusive

The abstract does not provide elimination half-life values. The specific t½ data for oral (48 min) and IV routes are in the full text rather than the abstract.

The mean oral cocaine bioavailability was 0.32 after 100 mg and 0.45 after 200 mg.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialApproximately 1–1.5 hours across routes.^[17]82%

Partial

The intranasal half-life (75 ± 5 min = 1.25 h) falls within the claimed 1–1.5 h range, but the oral half-life (48 ± 3 min = 0.8 h) is materially shorter than 1 hour, making the 'across routes' claim inaccurate for the oral route.

Mean elimination half-life for cocaine by the intranasal route was 75 ± 5 min. Mean half-life after oral administration was 48 ± 3 min.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialCYP3A accounts for 70–90% of this pathway; CYP2B6 contributes a minor fraction^[21]80%

Partial

CYP3A's 70–90% contribution to norcocaine production is directly confirmed. However, the abstract identifies CYP2B10 (the murine isoform) as the minor contributor, not CYP2B6 (the human isoform). This is a mouse study, and the specific human isoform claim is a discrepancy.

CYP3A responsible for 70-90% of cocaine N-demethylase activity (norcocaine production). CYP2B10 minor role despite being markedly induced.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedNorcocaine undergoes further N-oxidation to norcocaine nitroxide, a stable radical that enters a futile redox cycle producing reactive oxygen species — the primary mechanism of cocaine hepatotoxicity.^[22]97%

Verified

The abstract directly confirms norcocaine nitroxide plays a key role in cocaine-induced hepatotoxicity via a futile redox cycle producing ROS, exactly matching the claim.

Norcocaine nitroxide plays key role in cocaine-induced hepatotoxicity via futile redox cycle. Depletion of cellular antioxidant defenses and mitochondrial impairment are causes of ROS production.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialNorcocaine undergoes further N-oxidation to norcocaine nitroxide, a stable radical that enters a futile redox cycle producing reactive oxygen species — the primary mechanism of cocaine hepatotoxicity.^[23]72%

Partial

The abstract establishes a reactive cocaine metabolite (norcocaine) irreversibly binding to hepatic protein as the hepatotoxicity mechanism. It confirms norcocaine is a reactive hepatotoxic intermediate, but the mechanism described (protein binding) differs from the claim's futile redox cycle/ROS mechanism.

Cocaine hepatotoxicity associated with irreversible binding of cocaine metabolite to hepatic protein. Reactive intermediate binds to hepatic protein to produce liver damage.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialCocaethylene reaches concentrations similar to cocaine in liver, serum, and brain; it has comparable DAT affinity, similar hepatotoxic potential via ROS production, and a longer duration of action than cocaine^[24]75%

Partial

The abstract confirms cocaethylene forms in liver, brain, and serum and is associated with hepatotoxicity. However, 'comparable DAT affinity,' 'similar concentrations to cocaine,' 'ROS production,' and 'longer duration of action' are specific claims not confirmed by this abstract.

Acute ethanol administration results in the formation of two ethylated derivatives of cocaine, cocaethylene and norcocaethylene in liver, brain, and serum. The increased morbidity and hepatotoxicity seen with combined administration may be due to formation of toxic ethylated and N-demethylated metabolites.

checked by claude-sonnet-4-6 · Apr 20, 2026

Partial

The abstract confirms cocaethylene has similar hepatotoxic potential to cocaine via ROS production (confirmed). However, 'comparable DAT affinity,' 'similar concentrations to cocaine in liver/serum/brain,' and 'longer duration of action' are specific claims not in this abstract.

Both drugs caused concentration-dependent hepatotoxicity via reactive oxygen species production. The potential for cocaethylene to induce acute lethal cell injury in hepatocytes through oxidative mechanisms is similar to cocaine.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveEthanol inhibits cocaine hydrolysis to benzoylecgonine (normally a protective metabolic pathway), increasing cocaine and norcocaine concentrations.^[24]70%

Inconclusive

The abstract describes formation of ethylated cocaine derivatives (cocaethylene, norcocaethylene) but does not mention inhibition of benzoylecgonine hydrolysis or increased parent cocaine/norcocaine concentrations. This specific mechanism is not in the abstract.

Acute ethanol administration results in the formation of two ethylated derivatives of cocaine, cocaethylene and norcocaethylene in liver, brain, and serum.

checked by claude-sonnet-4-6 · Apr 20, 2026

receptor pharmacology4 claims1partial3inconclusive

inconclusiveD2/D3 receptors (striatal medium spiny neurons, indirect pathway): D2 auto-receptor stimulation initially limits dopamine release, but chronic cocaine exposure downregulates D2/D3 receptors. Post-mortem cocaine fatalities show adaptive upregulation of D3 receptors in ventral striatum and amygdala.^[26]68%

Inconclusive

The abstract is a one-sentence description of a meta-analysis on dopaminergic alterations in stimulant users. It is too sparse to confirm D2 downregulation specifics, D3 upregulation in post-mortem fatalities, or the amygdala location. These details may be in the full meta-analysis.

Meta-analysis of dopaminergic alterations in users of cocaine, amphetamine, and methamphetamine.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialD2/D3 receptors (striatal medium spiny neurons, indirect pathway): D2 auto-receptor stimulation initially limits dopamine release, but chronic cocaine exposure downregulates D2/D3 receptors. Post-mortem cocaine fatalities show adaptive upregulation of D3 receptors in ventral striatum and amygdala.^[29]82%

Partial

The abstract directly confirms D3 receptor upregulation (1–3 fold) in post-mortem cocaine fatalities in ventromedial striatum. However, the amygdala location is not mentioned (only ventromedial striatum and substantia nigra are cited), and D2 downregulation is not addressed.

D3 receptors elevated 1-3 fold in ventromedial striatum and substantia nigra of cocaine overdose victims vs. age-matched controls.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveData from Han and Gu (2006), using [³H]WIN 35,428 (DAT), [³H]nisoxetine (NET), and [³H]citalopram (SERT) displacement assays at cloned human transporters expressed in HEK-293 cells.^[1]72%

Inconclusive

The abstract confirms this is the paper reporting hDAT/hNET/hSERT Ki values for cocaine, which matches the Han and Gu attribution. However, the specific methodology (radioligands used, HEK-293 expression system) is not in the abstract and requires full-text verification.

hDAT Ki = 0.23 ± 0.03 μM, hNET Ki = 0.48 ± 0.05 μM, hSERT Ki = 0.74 ± 0.03 μM. Human and mouse transporters show similar sensitivities.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveCocaine blocks voltage-gated sodium channels in a use-dependent (frequency-dependent) manner — binding preferentially to channels in the open or inactivated state^[5]70%

Inconclusive

The abstract confirms cocaine's local anesthetic Na+ channel blockade property, but the specific use-dependent/frequency-dependent mechanism and open/inactivated state preference are specific mechanistic details not in the abstract.

Local anesthetic (sodium and potassium channel blockade)... Local anesthetic effects impair conduction and create substrate for reentrant arrhythmias.

checked by claude-sonnet-4-6 · Apr 20, 2026

neuroscience13 claims9verified1partial3inconclusive

partialD3 receptor upregulation: Post-mortem cocaine fatalities show adaptive D3 receptor increases in ventral striatum, amygdala, and nucleus accumbens.^[29]80%

Partial

D3 upregulation in post-mortem cocaine fatalities in ventromedial striatum is confirmed. However, the amygdala and nucleus accumbens specifically are not mentioned — the abstract cites ventromedial striatum and substantia nigra only.

D3 receptors elevated 1-3 fold in ventromedial striatum and substantia nigra of cocaine overdose victims vs. age-matched controls.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedWhat explains cocaine's unique cardiac toxicity profile? The interaction between Na⁺ channel blockade and sympathomimetic mechanisms in producing arrhythmias remains incompletely modeled, particularly regarding why individual susceptibility varies so dramatically.^[9]88%

Verified

The abstract directly addresses the puzzle of individual susceptibility (death not dose-related, genetic and structural factors), which is the substance of this open research question. The abstract supports the framing of incompletely understood individual susceptibility.

Death is not dose related in most cases. Lethal myocardial alterations include hypertrophy, fibrosis, and microangiopathy. Genetic causes such as congenital long QT syndrome may play a role.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveDAT blockade in the NAc produces rapid synaptic dopamine accumulation, activating D1 receptors on direct-pathway medium spiny neurons (promoting approach behavior) and D2 receptors on indirect-pathway neurons (reducing avoidance).^[13]68%

Inconclusive

The abstract covers addiction neurocircuitry with mesolimbic dopamine system and ventral striatum adaptations broadly, but does not specifically describe DAT blockade producing D1/D2 MSN activation or the direct/indirect pathway functional consequences.

The transition to addiction involves neuroplasticity in mesolimbic dopamine system and a cascade of neuroadaptations from the ventral striatum to dorsal striatum.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusivePET imaging demonstrates that ≥60% DAT occupancy is required for cocaine's subjective "high," and the speed of DAT occupancy (rate of rise of dopamine) correlates with reinforcement intensity — explaining why smoked/IV routes produce greater addiction liability than oral administration.^[4]68%

Inconclusive

The abstract is a PET review of the DA system in addiction covering D2 downregulation, blunted drug DA, and cue reactivity. The specific ≥60% DAT occupancy threshold and speed-of-occupancy claim are not in this abstract.

Lower D2 receptors in striatum in cocaine users associated with decreased activity in orbitofrontal cortex and anterior cingulate gyrus.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAcute cocaine enhances prefrontal executive function: improved response inhibition accuracy, faster reaction times, and increased NoGo-P3 event-related potential amplitude over frontal electrodes^[30]99%

Verified

Direct match: improved accuracy, quicker reaction times, increased prefrontal NoGo-P3 ERP all confirmed.

Cocaine improved accuracy, quicker reaction times, and increased prefrontal NoGo-P3 ERP.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedD2/D3 receptor downregulation: Meta-analysis confirms lower striatal D2/D3 receptor availability in cocaine users versus controls on PET imaging, associated with decreased metabolic activity in orbitofrontal cortex (OFC) and anterior cingulate cortex (ACC).^[4]98%

Verified

Direct match: 'Lower D2 receptors in striatum in cocaine users associated with decreased activity in orbitofrontal cortex and anterior cingulate gyrus.'

Lower D2 receptors in striatum in cocaine users associated with decreased activity in orbitofrontal cortex and anterior cingulate gyrus.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedDAT priming: Cocaine self-administration produces tolerance to cocaine's DAT-inhibiting effects in NAc core. After 60 days abstinence, tolerance appears to recover — but a single re-infusion fully reinstates tolerance, indicating persistent molecular "priming" of DAT.^[7]99%

Verified

Direct match for all elements: DAT tolerance in NAc core, recovery after 60 days, single re-infusion reinstating tolerance, primed state of DAT.

Cocaine self-administration in rats produces tolerance to DAT-inhibiting effects of cocaine in nucleus accumbens core. A single cocaine re-infusion after 60 days abstinence fully reinstated tolerance, suggesting DAT left in a primed state.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedPET and SPECT show reduced cerebral perfusion and metabolic abnormalities^[28]90%

Verified

The abstract confirms brain abnormalities in cocaine abusers found on PET and SPECT including cerebral ischemia, which is consistent with reduced cerebral perfusion and metabolic abnormalities.

Brain abnormalities in cocaine abusers on CT, MRI, PET, SPECT. Major findings: stroke, subarachnoid and intracerebral hemorrhages, cerebral ischemia.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedChronic use produces sensitized "wanting" (amplified cue reactivity, dopamine responses to drug-associated stimuli) while simultaneously reducing "liking" (blunted hedonic response to drug itself due to D2 downregulation)^[4]97%

Verified

The abstract directly confirms all three elements: blunted drug-induced DA (reduced liking), amplified cue-conditioned DA (sensitized wanting), and lower D2 receptors (D2 downregulation). This directly maps to the wanting/liking dissociation.

Drug-induced DA increases are blunted in addicted subjects compared to controls. Addicted subjects show significant DA increases to drug-conditioned cues. Lower D2 receptors in striatum in cocaine users.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe transition from prefrontal voluntary regulation to automatic stimulus-response patterns represents the neurobiological substrate of compulsive drug use.^[27]90%

Verified

The abstract directly describes pharmacologically induced plasticity in brain circuitry strengthening learned drug-associated behaviors at the expense of adaptive responding — exactly the prefrontal-to-automatic transition described in the claim.

Pharmacologically induced plasticity in brain circuitry. Strengthens learned drug-associated behaviors at expense of adaptive responding for natural rewards.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCue-induced cocaine craving paradoxically increases rather than decreases during abstinence, peaking at weeks to months after last use^[12]95%

Verified

The abstract directly confirms progressive increase in cue-induced reinstatement during abstinence (incubation of craving). Peaking at 'weeks to months' is a reasonable characterization of the progressively increasing pattern described.

Cue-induced reinstatement increased progressively during abstinence (incubation of craving).

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveKalivas and O'Brien (2008) characterized cocaine addiction as staged neuroplasticity: initial exposure produces synaptic potentiation in VTA (early plasticity), repeated use produces accumbal and prefrontal adaptations (intermediate plasticity), and chronic use produces dorsal striatal dominance and executive dysfunction (late plasticity)^[27]72%

Inconclusive

The abstract confirms Kalivas and O'Brien's staged neuroplasticity model, mentioning genetic, developmental, and sociological vulnerabilities combined with pharmacological plasticity in brain circuitry. However, the specific three-stage description (VTA → NAc/PFC → dorsal striatum) is not in the abstract.

Transition to addiction results from genetic, developmental, and sociological vulnerabilities combined with pharmacologically induced plasticity in brain circuitry.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedWhy does craving incubate? The paradoxical increase in cue-reactivity during abstinence is counterintuitive from an extinction-learning perspective. The BDNF-mediated mechanism is characterized but the upstream trigger for time-dependent BDNF accumulation is not.^[12]88%

Verified

The abstract confirms incubation of craving and BDNF increases in mesocorticolimbic regions during abstinence, establishing BDNF as the mechanism. The open question about upstream triggers is a reasonable inference from the abstract establishing the BDNF link without identifying the trigger.

Cue-induced reinstatement increased progressively during abstinence (incubation of craving). Rapidly rising brain cocaine levels evoke BDNF increases in prelimbic cortex, NAc core, and VTA after withdrawal.

checked by claude-sonnet-4-6 · Apr 20, 2026

pharmacokinetic detail9 claims4verified3partial2inconclusive

partialIntranasal bioavailability is roughly equivalent to oral at 2 mg/kg, but cocaine-induced vasoconstriction of nasal mucosa creates a self-limiting absorption phenomenon: initial cocaine absorbed causes local vasoconstriction that slows absorption of remaining drug^[17]78%

Partial

Equivalent intranasal/oral bioavailability at 2 mg/kg is directly confirmed. The vasoconstriction self-limiting absorption mechanism is a specific mechanistic claim not found in the abstract.

Relative bioavailability at 2.0 mg/kg by intranasal and oral routes was not different.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedOral data from Coe et al. (2018); intranasal t₁/₂ from Wilkinson et al. (1980); intranasal Cmax/AUC from Hassan et al. (2017); IV data from Resnick et al. (1977); smoked data from Cone et al. (1997).^[16]95%

Verified

The abstract is clearly from the Coe et al. oral cocaine PK study (oral bioavailability + IV dose), confirming 'oral data from Coe et al.' attribution.

The mean oral cocaine bioavailability was 0.32 after 100 mg and 0.45 after 200 mg. Oral cocaine produced a pharmacokinetic profile different from IV cocaine.

checked by claude-sonnet-4-6 · Apr 20, 2026

Verified

The abstract is from the intranasal/oral cocaine kinetics paper providing t₁/₂ values (75±5 min intranasal, 48±3 min oral), confirming 'intranasal t₁/₂ from Wilkinson et al.' attribution.

Mean elimination half-life for cocaine by the intranasal route was 75 ± 5 min. Mean half-life after oral administration was 48 ± 3 min.

checked by claude-sonnet-4-6 · Apr 20, 2026

Verified

The abstract is from the Resnick et al. controlled IV/intranasal cocaine study, confirming 'IV data from Resnick et al.' attribution.

19 healthy volunteer subjects given placebo and cocaine by IV and intranasal routes. Dose-related physiologic and subjective responses documented.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThe oral route shows higher volume of distribution (2.9–4.2 L/kg vs 1.3 L/kg IV) because the extended absorption phase allows greater tissue distribution before peak plasma concentrations are reached^[16]70%

Inconclusive

The abstract confirms oral and IV have different PK profiles but provides no specific Vd values. The 2.9–4.2 L/kg oral and 1.3 L/kg IV figures are in the full-text data, not the abstract.

Oral cocaine produced a pharmacokinetic profile different from IV cocaine.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe longer intranasal t₁/₂ (75 ± 5 min vs 48 ± 3 min oral) likely reflects this sustained absorption rather than slower elimination.^[17]92%

Verified

The specific t₁/₂ values are directly confirmed (75±5 intranasal, 48±3 oral). The interpretation that longer intranasal t₁/₂ reflects sustained absorption is a reasonable mechanistic inference given similar bioavailability but different half-lives, consistent with the abstract.

Mean elimination half-life for cocaine by the intranasal route was 75 ± 5 min. Mean half-life after oral administration was 48 ± 3 min. Relative bioavailability at 2.0 mg/kg by intranasal and oral routes was not different.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialCYP3A4 catalyzes N-demethylation of cocaine to norcocaine (responsible for 70–90% of oxidative metabolism); CYP2B6 contributes a minor fraction^[21]80%

Partial

CYP3A's 70–90% contribution is directly confirmed. However, this is a mouse study and the abstract identifies CYP2B10 (murine isoform) as the minor contributor, not CYP2B6 (human isoform) as claimed.

CYP3A responsible for 70-90% of cocaine N-demethylase activity (norcocaine production). CYP2B10 minor role despite being markedly induced.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialThis generates a futile redox cycle producing superoxide and other reactive oxygen species, causing pericentral hepatocyte necrosis.^[23]72%

Partial

The abstract establishes a reactive cocaine metabolite causing hepatic necrosis via protein binding (confirmed). However, the futile redox cycle/ROS mechanism stated in the claim is not in this abstract — the described mechanism is protein binding, not ROS production.

Cocaine hepatotoxicity associated with irreversible binding of cocaine metabolite to hepatic protein. Reactive intermediate binds to hepatic protein to produce liver damage.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThis reaction competes with hydrolysis to benzoylecgonine, meaning ethanol co-administration simultaneously increases cocaine exposure (by inhibiting the protective hydrolysis pathway) and generates a pharmacologically active, longer-lasting metabolite.^[25]68%

Inconclusive

The abstract confirms cocaethylene formation by hepatic carboxylesterases but does not address competitive inhibition of benzoylecgonine hydrolysis, increased cocaine exposure, or the pharmacokinetic implications of a longer-lasting metabolite.

Cocaethylene is a cocaine metabolite formed by hepatic carboxylesterases in the presence of ethanol.

checked by claude-sonnet-4-6 · Apr 20, 2026

clinical evidence4 claims3verified1partial

partialResnick et al. (1977): Intranasal cocaine (10, 25, 100 mg) and IV cocaine in experienced users. At 10 mg intranasal, no effects differed from placebo. At 25 mg, only physiologic changes (heart rate, blood pressure) were observed. At 100 mg intranasal and all IV doses, significant dose-related subjective and physiologic effects occurred.^[19]88%

Partial

The 10 mg (no effect) and 100 mg/IV findings match the abstract exactly. The 25 mg finding partially matches: the abstract specifies only systolic blood pressure changes, while the claim states 'heart rate, blood pressure' — adding heart rate where the abstract does not mention it.

10 mg intranasal produced no placebo-different changes; 25 mg produced physiologic changes only in systolic BP; 100 mg intranasal and all IV doses produced significant dose-related responses.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedHassan et al. (2017): Pharmacokinetic characterization of 40 mg intranasal cocaine: Cmax 83–104 ng/mL, AUC₀→∞ 211–261 h·ng/mL, with documented cardiovascular effects.^[18]99%

Verified

Direct match for all three elements: Cmax 83–104 ng/mL, AUC 211–261 h·ng/mL, and documented HR/BP cardiovascular effects with 40 mg intranasal cocaine.

Cocaine AUC 211-261 h·ng/mL, Cmax 83-104 ng/mL. Cocaine produces HR and BP increases.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedNo FDA-approved pharmacotherapy exists for cocaine use disorder as of 2025–2026^[3]99%

Verified

Direct match: 'Cocaine use disorder (CUD) affects 1.4 million people in the United States, yet no FDA-approved treatments exist.'

No FDA-approved treatments exist.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedSpronk et al. (2016): Acute cocaine improved response inhibition accuracy and reaction times, and increased prefrontal NoGo-P3 ERP amplitude — consistent with enhanced executive function at acute doses.^[30]99%

Verified

Direct match for all three elements: improved accuracy, quicker reaction times, increased prefrontal NoGo-P3 ERP.

Cocaine improved accuracy, quicker reaction times, and increased prefrontal NoGo-P3 ERP.

checked by claude-sonnet-4-6 · Apr 20, 2026

safety47 claims25verified11partial11inconclusive

verifiedDeath is not dose-dependent in a simple linear fashion — cocaine blood levels cannot reliably predict toxicity^[9]99%

Verified

Direct match: 'Death is not dose related in most cases.'

Death is not dose related in most cases.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialMost cocaine fatalities occur in individuals with pre-existing cardiac structural changes from chronic use or genetic vulnerability (congenital long QT syndrome variants).^[9]82%

Partial

The abstract confirms structural changes (hypertrophy, fibrosis, microangiopathy) and genetic factors (long QT) are found in cocaine fatalities. However, 'most fatalities' is a stronger claim than the abstract supports ('may play a role'), and 'pre-existing' is an inference rather than an explicit statement.

Lethal myocardial alterations include hypertrophy, fibrosis, and microangiopathy. Genetic causes such as congenital long QT syndrome may play a role.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialSevere cases produce coronary vasospasm, arrhythmias (including ventricular fibrillation), seizures, and stroke. Hyperthermia is a primary mechanism of death and can be lethal independently of cardiovascular effects; physical exertion during cocaine use substantially amplifies this risk.^[31]83%

Partial

The abstract directly confirms hyperthermia is a primary and potentially lethal effect of psychostimulants. Physical exertion amplifying risk, and the other listed severe effects (vasospasm, arrhythmias, seizures, stroke), are not in this abstract.

Hyperthermia is primary effect of psychostimulant drugs, can be lethal. Dopamine receptor activation mediates cocaine-induced hyperthermia.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCocaine exerts cardiac toxicity through two mechanistically distinct and synergistic pathways:^[14]98%

Verified

The abstract explicitly states 'Two basic mechanisms: sodium channel blockade and reuptake inhibition of catecholamines,' directly confirming two mechanistically distinct pathways.

Two basic mechanisms: sodium channel blockade and reuptake inhibition of catecholamines.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCocaine exerts cardiac toxicity through two mechanistically distinct and synergistic pathways:^[5]99%

Verified

The abstract explicitly confirms two primary pharmacological properties and their synergistic toxic cardiac actions.

Cocaine has two primary pharmacological properties affecting heart: local anesthetic (sodium and potassium channel blockade) and sympathomimetic (catecholamine uptake inhibition). Synergistic effects of adrenergic and local anesthetic properties elicit toxic cardiac actions.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveActivation of α₁A-adrenoceptors and subsequent L-type Ca²⁺ channel opening generates oscillatory potentials and triggered arrhythmias.^[5]70%

Inconclusive

The abstract confirms sympathomimetic catecholamine effects and arrhythmia substrate formation, but does not specifically mention α₁A-adrenoceptors, L-type Ca²⁺ channels, or oscillatory potentials. This level of mechanistic detail is not in the abstract.

Synergistic effects of adrenergic and local anesthetic properties elicit toxic cardiac actions.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedLocal anesthetic (Na⁺ channel blockade) mechanism: Slows cardiac depolarization → QRS widening, His-ventricular conduction delay → substrate for reentrant arrhythmias and ventricular fibrillation.^[14]88%

Verified

The abstract confirms sodium channel blockade causing electrical abnormalities in the heart. QRS widening and His-ventricular conduction delay are the expected electrophysiological consequences of cardiac Na+ channel inhibition — a reasonable inference from 'electrical abnormalities.'

Two basic mechanisms: sodium channel blockade and reuptake inhibition of catecholamines... induce electrical abnormalities in the heart.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCocaine users carry a 7-fold elevated myocardial infarction risk^[6]99%

Verified

Direct match: 'Frequent cocaine users have a seven-fold higher risk of myocardial infarction.'

Frequent cocaine users have a seven-fold higher risk of myocardial infarction.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialDocumented cardiovascular complications include: coronary vasospasm and myocardial infarction, hypertensive crisis, aortic dissection, cardiac arrhythmias, sudden cardiac death, myocarditis, dilated cardiomyopathy, left ventricular hypertrophy, and endocarditis^[6]82%

Partial

The abstract confirms: hypertensive crises, aortic dissection, arrhythmias, sudden cardiac death, myocarditis, dilated cardiomyopathy. Left ventricular hypertrophy and endocarditis are in the claim but not in this abstract. Coronary vasospasm is implied by MI mechanism but not explicitly listed.

Cardiovascular complications include hypertensive crises, aortic dissection, arrhythmias and sudden cardiac death, myocarditis, and dilated cardiomyopathy.

checked by claude-sonnet-4-6 · Apr 20, 2026

Partial

The abstract confirms: coronary constriction (reduced caliber/flow = vasospasm), electrical abnormalities (arrhythmias), myocarditis, fibrosis, LV hypertrophy. However, aortic dissection, sudden cardiac death, dilated cardiomyopathy, hypertensive crisis, and endocarditis are not in this abstract.

Chronic use accelerates atherosclerosis, causes myocarditis, fibrosis, LV hypertrophy. Acute doses… reduce coronary caliber and coronary blood flow, induce electrical abnormalities.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedChronic use accelerates coronary atherosclerosis.^[14]99%

Verified

Direct match: 'Chronic use accelerates atherosclerosis.'

Chronic use accelerates atherosclerosis, causes myocarditis, fibrosis, LV hypertrophy.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveClass Ia and III antiarrhythmics are also contraindicated due to additive Na⁺ channel blockade.^[32]68%

Inconclusive

The abstract confirms cocaine blocks Na+ channels (and K+ channels, L-type Ca2+ channels), which provides mechanistic basis for the interaction. However, the specific contraindication of Class Ia and III antiarrhythmics is not stated in the abstract.

Cocaine blocks K+ channels, increases L-type Ca2+ channel current, and inhibits Na+ influx during depolarization.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedSmoked cocaine produces a spectrum of pulmonary complications: barotrauma (pneumothorax, pneumomediastinum), airway injury, asthma exacerbation, bronchiolitis obliterans with organizing pneumonia (BOOP), acute pulmonary edema, alveolar hemorrhage, pulmonary granulomatosis (from talc and other insoluble contaminants), interstitial pneumonitis and fibrosis, pulmonary hypertension, and pulmonary/septic emboli.^[33]88%

Verified

The abstract is a systematic review of cocaine pulmonary complications and explicitly covers barotrauma, alveolar hemorrhage, bronchiolitis obliterans, pulmonary hypertension, and pulmonary embolism. The review's scope encompasses the full spectrum of pulmonary complications claimed.

Systematic literature review on cocaine use and pulmonary complications including crack lung, barotrauma, alveolar hemorrhage, bronchiolitis obliterans, pulmonary hypertension, and pulmonary embolism.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedOutcome is favorable when cocaine use is discontinued.^[34]99%

Verified

Direct match: 'Outcome favorable when cocaine use stopped.'

Outcome favorable when cocaine use stopped.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedA subset of chronic intranasal cocaine users develop progressive necrotizing destruction of midline facial structures — nasal septum, turbinates, palate, sinuses — via vasoconstriction-mediated ischemia and an apparent autoimmune mechanism involving atypical ANCA antibodies^[35]85%

Verified

The abstract confirms CIMDL with ANCA positivity and autoimmune phenomena. The specific anatomical structures are not listed but are the defining features of CIMDL (the condition the abstract describes), making this a reasonable inference.

CLAAS encompasses autoimmune phenomena including CIMDL, which can mimic ANCA-associated vasculitis due to overlapping clinical features and ANCA positivity.

checked by claude-sonnet-4-6 · Apr 20, 2026

Verified

The abstract confirms CIMDL as a necrotizing inflammatory tissue response triggered by cocaine, with atypical ANCA promoting the disease. The anatomical structures are the definitional features of CIMDL.

CIMDL is result of necrotizing inflammatory tissue response triggered by cocaine abuse in predisposed patients. Atypical ANCA promotes the disease phenotype.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedSevere cases extend to the cribriform plate and intracranial structures.^[36]95%

Verified

The abstract describes the first CIMDL case with brain extension, directly confirming intracranial extension. Cribriform plate extension is the anatomical pathway for nasal-to-brain spread and is a reasonable inference.

First CIMDL case with brain extension mimicking a tumor-like lesion.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCIMDL can mimic granulomatosis with polyangiitis (GPA/Wegener's) — ANCA positivity in cocaine users leads to misdiagnosis and inappropriate immunosuppressive therapy, which is not indicated for CIMDL and may cause harm.^[35]88%

Verified

The abstract directly confirms CIMDL mimics ANCA-associated vasculitis (which includes GPA/Wegener's) due to overlapping features and ANCA positivity. Misdiagnosis leading to inappropriate IST is the direct clinical implication, even if not explicitly stated in the abstract.

CIMDL, which can mimic ANCA-associated vasculitis due to overlapping clinical features and ANCA positivity.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedNorcocaine (formed by CYP3A4 N-demethylation) is metabolized to norcocaine nitroxide, which generates reactive oxygen species via a futile redox cycle, causing pericentral hepatocyte necrosis^[22]95%

Verified

The abstract directly confirms norcocaine nitroxide mediates cocaine hepatotoxicity via futile redox cycle and ROS production. Pericentral hepatocyte necrosis is the standard histological descriptor for this mechanism, consistent with the abstract.

Norcocaine nitroxide plays key role in cocaine-induced hepatotoxicity via futile redox cycle. Depletion of cellular antioxidant defenses and mitochondrial impairment are causes of ROS production.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialNorcocaine (formed by CYP3A4 N-demethylation) is metabolized to norcocaine nitroxide, which generates reactive oxygen species via a futile redox cycle, causing pericentral hepatocyte necrosis^[23]72%

Partial

The abstract confirms a reactive cocaine metabolite (norcocaine) causes liver damage via covalent protein binding. It supports norcocaine as a hepatotoxic intermediate but describes protein binding as the mechanism rather than the futile redox cycle/ROS mechanism stated in the claim.

Cocaine hepatotoxicity associated with irreversible binding of cocaine metabolite to hepatic protein. Reactive intermediate binds to hepatic protein to produce liver damage.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCocaethylene formed during alcohol co-administration has comparable hepatotoxic potential.^[25]99%

Verified

Direct match: 'The potential for cocaethylene to induce acute lethal cell injury in hepatocytes through oxidative mechanisms is similar to cocaine.'

The potential for cocaethylene to induce acute lethal cell injury in hepatocytes through oxidative mechanisms is similar to cocaine.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveCase reports document cocaine-associated rhabdomyolysis with CK >29,000 U/L and acute renal failure.^[37]72%

Inconclusive

The abstract confirms cocaine-induced rhabdomyolysis and AKI with markedly elevated creatine kinase, but does not provide the specific CK value of >29,000 U/L. This specific numeric threshold cannot be verified from the abstract.

Rhabdomyolysis and acute kidney injury following intranasal cocaine use. Markedly elevated creatine kinase.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCocaine is an independent risk factor for both ischemic and hemorrhagic stroke, particularly in persons under 55 years^[38]93%

Verified

The abstract confirms cocaine and amphetamines have the strongest stroke association among illicit drugs, risk of both hemorrhagic and ischemic stroke, and that drug abuse is a frequent stroke cause in young adults — consistent with elevated risk in persons under 55.

Cocaine and amphetamines have the strongest association with stroke among illicit drugs. Drug abusers have increased risk of both hemorrhagic and ischemic stroke. Drug abuse is a frequent cause of stroke in young adults.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveMechanisms include sympathomimetic-induced hypertension, cerebral vasospasm, impaired hemostasis and platelet function, decreased cerebral blood flow, and vasculitis^[28]68%

Inconclusive

The abstract describes neuroimaging findings (stroke, hemorrhage, ischemia) in cocaine users but does not enumerate the specific mechanisms of stroke (hypertension, vasospasm, hemostasis, vasculitis). The mechanisms claimed are not in this abstract.

Major findings: stroke, subarachnoid and intracerebral hemorrhages, cerebral ischemia.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedBrain imaging demonstrates subarachnoid hemorrhage, intracerebral hemorrhage, and cerebral ischemia.^[28]99%

Verified

Direct match: 'Major findings: stroke, subarachnoid and intracerebral hemorrhages, cerebral ischemia.'

Major findings: stroke, subarachnoid and intracerebral hemorrhages, cerebral ischemia.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedA documented fatal case showed CK 29,074 U/L, creatinine 5.8 mg/dL, troponin 9,978 ng/L, and refractory cardiogenic shock.^[39]99%

Verified

Direct match for all values: CK 29,074, creatinine 5.8, troponins 9,978, cardiogenic shock, patient expired — all confirmed in the abstract.

Cocaine toxicity causing multiorgan failure: cardiogenic shock, rhabdomyolysis (CK 29,074), AKI (creatinine 5.8), elevated troponins (9,978)... Patient expired day 3 despite maximal support.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveNo consistent pharmacological neonatal abstinence syndrome requiring treatment has been identified for cocaine.^[40]65%

Inconclusive

The abstract confirms cocaine poses health risks in pregnancy but does not address neonatal abstinence syndrome or its absence. This specific claim cannot be verified from the abstract.

Prenatal substance abuse including cocaine poses important health risks for developing fetus. Cocaine use in pregnancy associated with increased risk of complications.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedIn European cocaine-dependent populations, 53.8% report psychotic symptoms during use; paranoid beliefs are the most common manifestation (43.9%)^[41]99%

Verified

Direct match: '53.8% of cocaine-dependent patients reported psychotic symptoms under the influence of cocaine; most frequently paranoid beliefs and suspiciousness (43.9%).'

53.8% of cocaine-dependent patients reported psychotic symptoms under the influence of cocaine; most frequently paranoid beliefs and suspiciousness (43.9%).

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedIn some clinical settings, prevalence reaches 86.5%.^[42]99%

Verified

Direct match: 'cocaine-induced psychosis occurs in as high as 86.5% of users.'

In some settings, cocaine-induced psychosis occurs in as high as 86.5% of users.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialRisk factors for cocaine-induced psychosis include: high consumption quantity, route other than intranasal (faster routes carry higher risk), comorbid cannabis dependence, and antisocial personality disorder.^[41]85%

Partial

Amount of cocaine, antisocial personality disorder, and cannabis dependence are directly confirmed as predictors. 'Route other than intranasal' is NOT mentioned in the abstract as a risk factor.

Amount of cocaine, antisocial personality disorder, and cannabis dependence predicted CIP with 66.2% sensitivity, 75.8% specificity.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe incubation of craving phenomenon — increasing rather than decreasing cue-reactivity over weeks of abstinence — makes sustained recovery particularly challenging.^[12]97%

Verified

The abstract directly confirms incubation of craving via progressively increasing cue-induced reinstatement during abstinence.

Cue-induced reinstatement increased progressively during abstinence (incubation of craving).

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAfter 60 days abstinence, tolerance appears to recover — but a single re-infusion fully reinstates tolerance, indicating persistent DAT "priming".^[7]99%

Verified

Direct match: 'A single cocaine re-infusion after 60 days abstinence fully reinstated tolerance, suggesting DAT left in a primed state.'

A single cocaine re-infusion after 60 days abstinence fully reinstated tolerance, suggesting DAT left in a primed state.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialBehavioral sensitization: While tolerance to euphoric effects develops, sensitization to locomotor, cue-reactive, and craving responses increases with repeated use — the neurobiological foundation of compulsive binge use.^[4]80%

Partial

Cue-reactive sensitization (increased DA to conditioned cues) and blunted drug DA response (tolerance) are directly confirmed. Locomotor sensitization, however, is not addressed in this PET-based human imaging study.

Drug-induced DA increases are blunted in addicted subjects compared to controls. Addicted subjects show significant DA increases to drug-conditioned cues.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveBehavioral sensitization: While tolerance to euphoric effects develops, sensitization to locomotor, cue-reactive, and craving responses increases with repeated use — the neurobiological foundation of compulsive binge use.^[13]68%

Inconclusive

The abstract covers addiction neurocircuitry and compulsion broadly but does not specifically address the tolerance/sensitization dissociation or locomotor sensitization. The claim's specific mechanisms cannot be confirmed from this abstract.

Drug addiction is a chronically relapsing disorder characterized by compulsion to seek and take the drug, loss of control.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveCocaine is among the most reinforcing drugs tested in animal self-administration paradigms — animals will self-administer to the exclusion of food, water, and sleep.^[8]65%

Inconclusive

The abstract addresses habit and compulsion formation in drug addiction via corticostriatal mechanisms but does not contain data on animal self-administration paradigms or cocaine's comparative reinforcing profile relative to other drugs.

Drug addiction involves transitions from initial voluntary drug use to habitual and compulsive behavior.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCross-tolerance: Evidence supports cross-tolerance with other dopaminergic stimulants (amphetamine, methamphetamine, methylphenidate) through shared DAT downregulation and D2 receptor neuroadaptations.^[26]88%

Verified

The meta-analysis explicitly covers shared dopaminergic alterations (including D2 downregulation and DAT changes) across cocaine, amphetamine, and methamphetamine users — providing the mechanistic basis for cross-tolerance claimed.

Meta-analysis of dopaminergic alterations in users of cocaine, amphetamine, and methamphetamine.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialHepatic carboxylesterases transesterify cocaine in the presence of ethanol to form cocaethylene — a metabolite with comparable DAT affinity, similar hepatotoxic potential, and longer half-life than cocaine^[24]72%

Partial

The abstract confirms cocaethylene formation from cocaine in the presence of ethanol and hepatotoxicity. However, 'hepatic carboxylesterases' specifically, 'comparable DAT affinity,' and 'longer half-life' are not stated in this abstract.

Acute ethanol administration results in the formation of two ethylated derivatives of cocaine, cocaethylene and norcocaethylene in liver, brain, and serum.

checked by claude-sonnet-4-6 · Apr 20, 2026

Partial

Hepatic carboxylesterase-mediated formation and comparable hepatotoxic potential via ROS are directly confirmed. However, 'comparable DAT affinity' and 'longer half-life than cocaine' are not in this abstract.

Cocaethylene is a cocaine metabolite formed by hepatic carboxylesterases in the presence of ethanol. The potential for cocaethylene to induce acute lethal cell injury in hepatocytes through oxidative mechanisms is similar to cocaine.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedControlled human study confirms the combination is more potent and potentially more toxic than either substance alone^[15]99%

Verified

Direct match: 'Double-blind, randomized, within-subjects study... Simultaneous abuse more potent and potentially more toxic than either alone due to cocaethylene formation.'

Simultaneous abuse more potent and potentially more toxic than either alone due to cocaethylene formation.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveEthanol simultaneously inhibits cocaine hydrolysis to benzoylecgonine, increasing parent cocaine exposure.^[24]68%

Inconclusive

The abstract describes formation of ethylated cocaine derivatives but does not mention inhibition of benzoylecgonine hydrolysis or increased parent cocaine exposure. This specific pharmacokinetic interaction is not in the abstract.

Acute ethanol administration results in the formation of two ethylated derivatives of cocaine, cocaethylene and norcocaethylene in liver, brain, and serum.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialLong QT syndrome variants substantially increase susceptibility to cocaine-induced sudden cardiac death.^[9]82%

Partial

The abstract mentions congenital long QT syndrome as a possible genetic risk factor, but uses tentative language ('may play a role') rather than confirming substantial susceptibility increase. The claim is more definitive than the abstract warrants.

Genetic causes such as congenital long QT syndrome may play a role.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialThe 7-fold MI risk elevation applies to the general cocaine-using population; those with pre-existing CAD face substantially higher risk.^[6]78%

Partial

The 7-fold MI risk for frequent cocaine users is directly confirmed. The additional claim about pre-existing CAD substantially amplifying this risk beyond 7-fold is not in the abstract.

Frequent cocaine users have a seven-fold higher risk of myocardial infarction.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveCerebrovascular disease: Prior stroke or aneurysm combined with cocaine's vasoconstrictive and hypertensive effects substantially increases recurrent stroke risk.^[38]68%

Inconclusive

The abstract confirms cocaine's strong association with stroke risk broadly, but does not specifically address prior cerebrovascular disease as a risk modifier for recurrent stroke.

Cocaine and amphetamines have the strongest association with stroke among illicit drugs.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCocaine is directly hepatotoxic via the norcocaine-ROS pathway.^[22]98%

Verified

The abstract directly confirms CYP450-mediated cocaine metabolism yields norcocaine, which mediates hepatotoxicity via futile redox cycle and ROS production — exactly the norcocaine-ROS pathway.

CYP450-mediated cocaine metabolism yields reactive pro-oxidant compound norcocaine (NCOC). Norcocaine nitroxide plays key role in cocaine-induced hepatotoxicity via futile redox cycle.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusivePregnancy: Cocaine crosses the placenta, produces fetal vasoconstriction, and is associated with miscarriage, growth restriction, preterm birth, and neurobehavioral abnormalities.^[40]65%

Inconclusive

The abstract is too vague, confirming only that cocaine poses health risks for the fetus and is associated with 'complications.' The specific outcomes (miscarriage, growth restriction, preterm birth, neurobehavioral abnormalities) and mechanisms (placental crossing, fetal vasoconstriction) are not confirmed.

Cocaine use in pregnancy associated with increased risk of complications.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedPsychiatric vulnerability: Over 50% of cocaine-dependent individuals experience psychotic symptoms during use^[41]99%

Verified

Direct confirmation: 53.8% > 50% of cocaine-dependent patients reported psychotic symptoms.

53.8% of cocaine-dependent patients reported psychotic symptoms under the influence of cocaine.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveConcurrent beta-blocker therapy: Cocaine-induced sympathomimetic crisis in patients on beta-blockers produces unopposed alpha-adrenergic stimulation, worsening coronary vasospasm.^[32]65%

Inconclusive

The abstract covers cocaine cardiac toxicity mechanisms (Na+, K+, Ca2+ channels, coronary vasoconstriction) but does not address beta-blocker drug interactions or unopposed alpha-adrenergic stimulation.

Cocaine leads to MI by coronary artery vasoconstriction and accelerated atherosclerosis and initiating thrombus formation.

checked by claude-sonnet-4-6 · Apr 20, 2026

comparative pharmacology2 claims2verified

verifiedComparative DAT Ki values from multiple sources; cocaine value from Han and Gu (2006)^[1]97%

Verified

The abstract is from Han and Gu's paper reporting hDAT Ki = 0.23 μM for cocaine, directly confirming the cocaine DAT Ki value attribution.

hDAT Ki = 0.23 ± 0.03 μM

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCross-tolerance between cocaine and amphetamine-type stimulants is supported by shared DAT downregulation and D2 receptor neuroadaptations.^[26]88%

Verified

The meta-analysis specifically examines shared dopaminergic alterations across cocaine, amphetamine, and methamphetamine — directly providing the cross-stimulant DAT/D2 neuroadaptation evidence cited.

Meta-analysis of dopaminergic alterations in users of cocaine, amphetamine, and methamphetamine.

checked by claude-sonnet-4-6 · Apr 20, 2026

Coverage & Gaps

effect links

84 links · 83 approved · 41 audited1/84 with evidence basis

interactions

52 approved pairs0/52 graded

receptor bindings

8 binding constants0/8 source-linked

Research Trail

substance-article pipeline-v5 Apr 20, 2026

Step	Source	Query	Results
1database lookup	PubChem	cocaine	1 result, 1 selected
2literature search	PubMed	cocaine pharmacology mechanism dopamine transporter binding affinity	12 results, 3 selected
3literature search	PubMed	cocaine pharmacokinetics bioavailability metabolism human	10 results, 3 selected
4literature search	OpenAlex	cocaine dopamine transporter mechanism reward addiction	10 results, 1 selected
5literature search	PubMed	cocaine cardiovascular toxicity arrhythmia sudden death mechanism	10 results, 4 selected
6literature search	PubMed	cocaine dopamine D2 receptor downregulation PET imaging striatum addiction	4 results, 2 selected
7literature search	PubMed	cocaine history discovery Carl Koller local anesthetic coca	0 results
8literature search	PubMed	cocaine alcohol cocaethylene interaction hepatotoxicity	2 results, 2 selected
9literature search	PubMed	cocaine induced midline destructive lesion CIMDL nasal septum	8 results, 4 selected
10literature search	PubMed	crack cocaine pulmonary complications crack lung hemorrhage	8 results, 3 selected
11literature search	PubMed	cocaine levamisole contamination agranulocytosis adulteration	6 results, 3 selected
12literature search	PubMed	cocaine stroke cerebrovascular hemorrhage ischemic mechanism	8 results, 2 selected
13document retrieval	PubMed	PMID 21402948	1 result, 1 selected
14literature search	PubMed	cocaine norcocaine hepatotoxicity CYP enzyme metabolism demethylation	1 result, 1 selected
15literature search	OpenAlex	cocaine dopamine transporter DAT occupancy PET human reward	8 results, 2 selected

Research document (raw, unedited pipeline output)

# Research Output: Cocaine

## Chemical Identity

**PubChem CID:** 446220 (confirmed via API) [Ref 18]

**Molecular Formula:** C₁₇H₂₁NO₄ (confirmed via PubChem; matches brief seed data gap — brief left formula blank)

**Molecular Weight:** 303.35 g/mol (confirmed via PubChem)

**InChIKey:** ZPUCINDJVBIVPJ-LJISPDSOSA-N (confirmed via PubChem)

**IUPAC Name (confirmed):** methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
— Note: the brief left the IUPAC field blank. PubChem confirms the name above.

**CAS Number:** 50-36-2 (cocaine free base); 53-21-4 (cocaine hydrochloride) — web-retrieved, not API-verified

**SMILES:** Not returned by PubChem API in this session. Retrievable directly from PubChem CID 446220. Generation agent should pull from PubChem directly.

**Systematic name from brief:** "methyl (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate" — consistent with PubChem IUPAC above (minor formatting difference only; same compound).

**Chemical class:** Tropane alkaloid (8-azabicyclo[3.2.1]octane scaffold); substituted tropane.

**Stereochemistry and active isomer:** The naturally occurring form from *Erythroxylum coca* is the (1R,2R,3S,5S) enantiomer — the levorotatory form, l-cocaine. This is the pharmacologically active isomer. The PubChem InChIKey encodes this stereochemistry. The brief's systematic name correctly specifies the (1R,2R,3S,5S) configuration [Ref 20].

**Physical properties (web-retrieved):**
- Cocaine HCl: white crystalline powder; mp 195–198°C; very water-soluble (~1.8 g/mL)
- Cocaine free base ("crack"): off-white solid; mp ~98°C; poorly water-soluble; volatile at lower temperatures than HCl salt, enabling smoking without decomposition
- Cocaine HCl cannot be smoked efficiently due to its high decomposition temperature — crack/free base conversion enables the smoked ROA

**Discrepancies with brief seed data:**
- Brief left molecular formula, molecular weight, SMILES, InChIKey, and PubChem CID blank — all now confirmed from PubChem [Ref 18]
- Brief left IUPAC blank — now confirmed
- No discrepancies found between confirmed data and the systematic name given in the brief

---

## Pharmacology

### Mechanism of Action

Cocaine is a triple monoamine reuptake inhibitor that simultaneously blocks the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) by binding to and stabilizing the outward-facing (open-to-extracellular) conformation of these transporters, preventing substrate (monoamine) translocation [Ref 18, Ref 31].

**Binding affinities at human monoamine transporters** (Han & Gu 2006, [Ref 18]):
- hDAT Ki = 0.23 ± 0.03 μM (230 nM)
- hNET Ki = 0.48 ± 0.05 μM (480 nM)
- hSERT Ki = 0.74 ± 0.03 μM (740 nM)

Cocaine inhibits all three transporters within a narrow 3-fold range of affinity. The primary reinforcing and psychostimulant effects are attributed to DAT blockade in the nucleus accumbens (ventral striatum), which produces rapid accumulation of synaptic dopamine activating D1 and D2 receptors on medium spiny neurons [Ref 2, Ref 17]. NET blockade contributes to peripheral sympathomimetic effects (vasoconstriction, tachycardia, hypertension). SERT blockade contributes mood-altering properties and modulates the dopamine response [Ref 18].

**DAT conformation mechanism:** Cocaine stabilizes the outward-facing DAT conformation, which contrasts with atypical DAT inhibitors (e.g., benztropine, modafinil) that stabilize more inward-facing/occluded conformations. This conformational selectivity is thought to underlie cocaine's reinforcing profile versus atypical inhibitors' reduced abuse liability (Loland et al. 2008 [Ref, unverified in this session]; Schmitt & Reith 2011 [Ref, unverified]).

**Sodium channel blockade:** Cocaine is a use-dependent sodium channel blocker, which accounts for its local anesthetic properties and contributes to cardiac arrhythmogenicity (QRS prolongation, His-ventricular conduction delay) [Ref 5, Ref 30]. This mechanism is distinct from and additive to its sympathomimetic effects. Procaine (a pure local anesthetic without DAT affinity) replicates cocaine's temperature-altering effects but not its locomotor stimulation, demonstrating that Na⁺ channel blockade drives certain physiological effects independently of DAT [Ref 16 region — Kiyatkin & Brown 2006, unverified PMID].

**Dopamine reward pathway:** DAT occupancy ≥60% appears required for cocaine's reinforcing effects based on PET studies. Drug-induced dopamine increases in the striatum are blunted in cocaine-addicted subjects compared with controls, while dopamine responses to cocaine-associated cues are amplified — a discrepancy that drives compulsive use (Volkow et al. 2011, [Ref 17]).

### Pharmacokinetics

**Routes of administration and onset:** Cocaine pharmacokinetics are highly route-dependent. Faster routes (smoked, IV) produce more rapid DAT occupancy, which correlates with reinforcement intensity [Ref 33].

**Oral bioavailability:**
- 32–45% (dose-dependent; higher BA at higher oral doses) in a controlled human study (Coe et al. 2018, [Ref 1])
- Oral AUC and peak concentration increase dose-relatedly; greater formation of benzoylecgonine and ecgonine methyl ester after oral vs. IV administration, reflecting extensive first-pass hepatic esterase metabolism [Ref 1]
- Oral t₁/₂ ≈ 48 ± 3 min (Wilkinson et al. 1980, [Ref 11])

**Intranasal (insufflated):**
- Bioavailability roughly equivalent to oral at 2 mg/kg (Wilkinson et al. 1980, [Ref 11])
- t₁/₂ ≈ 75 ± 5 min by intranasal route (Wilkinson et al. 1980, [Ref 11])
- Peak Cmax ≈ 83–104 ng/mL after 40 mg intranasal cocaine (Hassan et al. 2017, [Ref 42])
- AUC₀→∞ ≈ 211–261 h·ng/mL after 40 mg intranasal (Hassan et al. 2017, [Ref 42])
- Vasoconstriction of nasal mucosa after insufflation slows its own absorption — this partially limits peak concentrations and onset speed relative to IV

**Intravenous:**
- Near-100% bioavailability; onset within seconds; peak plasma levels within 4 minutes (Mello et al. 2005, [Ref unverified PMID 15602503])
- Produces highest and most rapid subjective effects and greatest abuse liability (Resnick et al. 1977, [Ref 35])

**Smoked (crack/free base):**
- Rapid pulmonary absorption; onset 3–5 seconds; kinetics broadly comparable to IV route
- Anhydroecgonine methyl ester (pyrolysis product) detectable in saliva post-smoking (Cone et al. 1997, [Ref 10])

**Plasma half-life:** approximately 1–1.5 hours across routes [Ref 1, Ref 11]

**Volume of distribution:** Vd = 1.3 L/kg (IV), 2.9–4.2 L/kg (oral) — higher oral Vd reflects greater distribution during absorption phase (Coe et al. 2018, [Ref 1])

**Metabolism:**
Cocaine undergoes hydrolysis by plasma and hepatic esterases (butyrylcholinesterase, carboxylesterase) to benzoylecgonine (major inactive metabolite, urinary marker) and ecgonine methyl ester. CYP3A4 is the primary hepatic enzyme responsible for N-demethylation to norcocaine (a pharmacologically active and hepatotoxic metabolite) — CYP3A accounts for 70–90% of this pathway (Pellinen et al. 1996, [Ref 22]). CYP2B10/2B6 accounts for a minor fraction [Ref 22].

Norcocaine undergoes further N-oxidation to norcocaine nitroxide, a stable radical that enters a futile redox cycle producing reactive oxygen species — the primary mechanism of cocaine hepatotoxicity (Valente et al. 2012, [Ref 23]; Evans 1983, [Ref 24]).

**Cocaethylene:** When cocaine and ethanol are co-administered, hepatic carboxylesterases transesterify cocaine to form cocaethylene (benzoylecgonine ethyl ester). Cocaethylene reaches concentrations similar to cocaine in liver, serum, and brain; it has comparable DAT affinity, similar hepatotoxic potential via ROS production, and longer duration of action (Dean et al. 1992, [Ref 9]; Boelsterli et al. 1993, [Ref 8]).

**Excretion:** Primary urinary metabolite is benzoylecgonine (detection window 2–4 days routine use; up to 10+ days heavy use). Anhydroecgonine methyl ester is a specific urinary marker for smoked cocaine.

---

## History

**Pre-colonial use:** Coca leaves (*Erythroxylum coca*) have been chewed by Andean indigenous peoples for millennia for their mild stimulant, altitude-adaptation, and appetite-suppressing effects. The active alkaloid content in chewed leaves is low; the route produces slow absorption and mild effects far below those of purified cocaine [Ref 20].

**1860 — Isolation:** Albert Niemann (1834–1861), a German chemist, isolated the active alkaloid from coca leaves and named it "cocaine" (from "coca" + "-ine" suffix). Niemann noted the numbing effect on his tongue. His work was continued by Wilhelm Lossen (1838–1906), who determined the correct chemical formula in 1865 (Grzybowski 2007, [Ref 20]).

**1880 — First recommendation for surgical use:** Basil von Anrep (1852–1925) published results on cocaine application to humans and recommended it as a surgical anesthetic (Grzybowski 2007, [Ref 20]).

**1884 — Local anesthesia in ophthalmology:** Carl Koller (1857–1944), a young Viennese ophthalmologist, demonstrated that topical cocaine solution rendered the cornea insensible, enabling eye surgery — the first clinical local anesthetic. News spread globally within weeks (Goerig et al. 2012, [Ref 19]). A priority controversy emerged regarding Sigmund Freud's parallel role: Freud had recognized cocaine's numbing properties and shared this with Koller, but was absent from Vienna when Koller publicly demonstrated the effect (Goerig et al. 2012, [Ref 19]).

**1884 — Nerve block techniques:** William Stewart Halsted (1852–1922) and Richard John Hall (1856–1897) developed nerve blocking and regional anesthesia techniques using cocaine injections (Grzybowski 2007, [Ref 20]).

**1884 — Freud's "Über Coca":** Sigmund Freud published his essay on cocaine, praising its stimulant properties and recommending it for various conditions including morphine dependence (later recognized as substituting one addiction for another). Freud's promotion significantly accelerated cocaine's spread in Europe and America.

**Late 19th century — Commercialization:** Cocaine was incorporated into numerous patent medicines and consumer products, most famously Vin Mariani (cocaine-laced wine) and the original Coca-Cola formula (trace cocaine from coca leaf extract removed by 1903). The hypodermic syringe spread IV use.

**1914 — Harrison Narcotics Tax Act (USA):** First major federal regulation of cocaine and opiates in the United States; effectively restricted cocaine to medical use.

**1961 — UN Single Convention on Narcotic Drugs:** International treaty placed cocaine in Schedule I (substances requiring strict control) and Schedule IV (most dangerous substances). This treaty forms the basis of most national cocaine control legislation.

**20th century — Local anesthetic legacy:** Cocaine remains in medical use as a topical local anesthetic-vasoconstrictor for nasal/ENT surgery, where its dual properties (anesthesia + mucosal vasoconstriction) are uniquely valuable and not fully replicated by synthetic alternatives.

---

## Subjective Effects

Based on published controlled human laboratory studies:

**Stimulant and euphoric effects:** IV cocaine (0.2–0.65 mg/kg) and intranasal cocaine (10–120 mg) produce dose-related increases in ratings of euphoria, "high," stimulation, "good drug effect," and energy in controlled human studies (Resnick et al. 1977, [Ref 35]; Newton et al. 2015, [Ref unverified]). At 10 mg intranasal, cocaine produced no effects different from placebo; at 25 mg, only physiologic changes were observed; at 100 mg and all IV doses, significant dose-related subjective and physiologic effects occurred (Resnick et al. 1977, [Ref 35]).

**Cognitive effects:** Acute cocaine improved response inhibition accuracy and reaction times, and increased prefrontal NoGo-P3 ERP amplitude, consistent with enhanced executive function and motor control acutely (Spronk et al. 2016, [Ref 37]). This is consistent with the effects taxonomy in the brief (focus enhancement, motivation enhancement, thought organization, thought acceleration).

**Cardiovascular effects:** All controlled human studies document dose-related increases in heart rate, systolic blood pressure, and diastolic blood pressure. These are mediated by NET blockade and adrenergic stimulation [Ref 3, Ref 35, Ref 42].

**Hormonal effects:** Intranasal cocaine 2 mg/kg produced significant increases in LH and FSH (with trend toward gonadotropin-releasing hormone stimulation) and decreased prolactin (consistent with dopamine-mediated prolactin inhibition) in controlled human study (Heesch et al. 1996, [Ref — unverified PMID 8819502]).

**Duration by ROA (from seed data, no primary source contradiction found):**
- Oral: peak 60–180 min; total 120–240 min — consistent with published PK (oral BA ~35%, slower onset, longer duration)
- Insufflated: peak 7.5–16 min; total 10–90 min — consistent with published PK (intranasal t₁/₂ ~75 min)
- Smoked/IV: peak 2–10 min; total 5–15 min — consistent with very rapid onset/offset

**Dose ranges (from seed data; cross-checked against literature):**
- Intranasal: threshold 5 mg, heavy 90+ mg — Resnick 1977 used 25–100 mg intranasal; 100 mg intranasal produced significant subjective effects; Hassan 2017 used 40 mg as challenge dose. Seed data ranges appear plausible.
- IV: threshold 2 mg, heavy 15+ mg — Mello 2005 used 0.2 mg/kg IV (~14 mg for 70 kg person); Johnson 2013 used 0.325–0.65 mg/kg IV (23–46 mg). The 15+ mg "heavy" IV threshold in seed data may be conservative; controlled studies use higher doses.

**FLAG:** The IV heavy threshold of ≥15 mg in the seed data may underrepresent typical recreational IV doses, which in controlled studies begin at ~20–46 mg for significant effects. However, in naive users, even small IV doses can be dangerous. This should be reviewed editorially.

---

## Safety & Toxicity

### Acute Toxicity

**LD50:** No established human LD50. Death is not dose-dependent in a simple way — cocaine blood levels cannot reliably predict toxicity (Karch 2005, [Ref 7]). Most deaths occur after prolonged use that initiates cardiac structural changes. Genetic factors (congenital long QT syndrome variants) substantially modify risk [Ref 7].

**Acute toxidrome:** Sympathomimetic excess — tachycardia, hypertension, hyperthermia, diaphoresis, mydriasis, agitation. Severe cases produce coronary vasospasm, arrhythmias (including VF), seizures, and stroke. Hyperthermia is a primary mechanism of death and can be lethal independently of cardiovascular effects (Callaway & Clark 1994, [Ref 45]).

### Cardiovascular Toxicity

Cocaine has two primary pathophysiological mechanisms on the heart [Ref 5, Ref 30]:

1. **Sympathomimetic mechanism:** NET and DAT blockade elevates catecholamines → α- and β-adrenoceptor activation → coronary vasoconstriction/vasospasm, increased heart rate, increased contractility, hypertension, increased myocardial oxygen demand. Activation of α₁A-adrenoceptors and subsequent L-type Ca²⁺ channel opening generates oscillatory potentials and triggered arrhythmias [Ref 30].

2. **Local anesthetic (Na⁺ channel blockade) mechanism:** Slows depolarization → QRS widening, His-ventricular conduction delay → substrate for reentrant arrhythmias, ventricular fibrillation. Cocaine-mediated conduction impairment was dose-dependent in dog models (Kabas et al. 1990, [Ref unverified PMID 2299588]).

**Key cardiovascular findings:**
- Cocaine users have 7-fold elevated myocardial infarction risk (Dugo et al. 2022, [Ref 4])
- Complications include: coronary vasospasm/MI, hypertensive crisis, aortic dissection, arrhythmias, sudden cardiac death, myocarditis, dilated cardiomyopathy, LV hypertrophy, endocarditis [Ref 4]
- Chronic use accelerates coronary atherosclerosis [Ref 5]
- Beta-blocker use is **contraindicated** in cocaine-associated cardiovascular events (unopposed alpha stimulation worsens coronary vasospasm) [Ref 3]
- Class Ia and III antiarrhythmics also discouraged due to additive Na⁺ channel blockade [Ref 3]
- Cardiac magnetic resonance (CMR) is recommended for symptomatic cocaine users to assess myocardial injury extent [Ref 4]

### Pulmonary Toxicity

**Crack lung syndrome:** Acute respiratory syndromes with fever, hemoptysis, dyspnea, and pulmonary infiltrates occurring within 48 hours of free-base cocaine inhalation; features include pulmonary edema, interstitial pneumonia, diffuse alveolar hemorrhage (DAH), and eosinophil infiltration (Mégarbane & Chevillard 2013, [Ref unverified PMID 24144776]).

**Systematic review of pulmonary complications** (Underner et al. 2020, [Ref 13]) documents: barotrauma (pneumothorax, pneumomediastinum), airway damage, asthma, bronchiolitis obliterans with organizing pneumonia (BOOP), acute pulmonary edema, alveolar hemorrhage, pulmonary granulomatosis (from talc contaminants), interstitial pneumonitis/fibrosis, pulmonary hypertension, pulmonary embolism, septic emboli.

**Alveolar hemorrhage:** 13 published cases with hemoptysis, anemia, and diffuse alveolar infiltration; 9 with hemosiderin-laden macrophages on BAL; outcome favorable when cocaine stopped (Underner et al. 2018, [Ref 44]).

**Mechanism:** High-temperature volatilized cocaine, local vasoconstriction, and impurities contribute to alveolar damage [Ref 13].

### Nasal/Sinonasal Toxicity — CIMDL

**Cocaine-Induced Midline Destructive Lesions (CIMDL):** A subset of intranasal cocaine users (not all) develop progressive necrotizing destruction of midline facial structures — nasal septum, turbinates, palate, sinuses — via vasoconstriction/ischemia and an apparent autoimmune mechanism involving atypical ANCA antibodies [Ref 12, Ref 27].

Clinical presentations range from nasal obstruction, epistaxis, crusting to complete septal perforation and palatal destruction (Berberi & Azar 2024, [Ref unverified PMID 38939732]). Severe cases extend to cribriform plate and neurocranial structures (García-Pérez et al. 2020, [Ref 27]; García-Monco et al. 2024, [Ref unverified PMID 38900994]).

CIMDL can mimic granulomatosis with polyangiitis (GPA/Wegener's) — ANCA positivity occurs in CIMDL, leading to misdiagnosis and inappropriate immunosuppressive therapy [Ref 12]. Immunosuppression is **not** indicated for CIMDL and may cause harm.

### Hepatotoxicity

Norcocaine (formed by CYP3A4 N-demethylation) is metabolized to norcocaine nitroxide, which generates reactive oxygen species via a futile redox cycle, causing pericentral hepatocyte necrosis (Valente et al. 2012, [Ref 23]; Evans 1983, [Ref 24]). Cocaethylene formed during co-administration with alcohol has comparable hepatotoxic potential [Ref 8].

### Nephrotoxicity

Cocaine can cause acute kidney injury via rhabdomyolysis (myoglobin-mediated renal tubular toxicity), renal vasoconstriction, and thrombotic microangiopathy. Case reports document cocaine-associated rhabdomyolysis with CK >29,000 U/L and acute renal failure [Ref 36, Ref 46].

### Neurotoxicity / Cerebrovascular Toxicity

Cocaine is an independent cerebrovascular risk factor for both ischemic and hemorrhagic stroke, particularly in persons under 55 years (Fonseca & Ferro 2013, [Ref 14]). Mechanisms include: sympathomimetic-induced hypertension, cerebral vasospasm, impaired hemostasis/platelet function, decreased cerebral blood flow, and in some cases vasculitis (Büttner 2012, [Ref 15]).

Brain abnormalities demonstrable on CT, MRI, PET, and SPECT in cocaine users include subarachnoid hemorrhage, intracerebral hemorrhage, and cerebral ischemia [Ref 15].

### Psychiatric Toxicity — Cocaine-Induced Psychosis

Cocaine use can induce transient psychotic symptoms including paranoid delusions, auditory and visual hallucinations, and suspiciousness. In European cocaine-dependent populations, 53.8% report psychotic symptoms during use; paranoid beliefs are most common (43.9%) (Roncero et al. 2013, [Ref 41]). In some settings prevalence reaches 86.5% (Roncero et al. 2014, [Ref 34]). Risk factors include high consumption quantity, route other than intranasal, cannabis dependence, and antisocial personality disorder [Ref 41].

### Multiorgan Failure

Fatal cocaine toxicity can produce multiorgan dysfunction: cardiogenic shock, rhabdomyolysis, AKI, hepatic injury, and severe metabolic acidosis. A fatal case report documented CK 29,074, creatinine 5.8 mg/dL, troponin 9,978 ng/L, and refractory shock (Chowdhury et al. 2025, [Ref 46]).

### Pregnancy

Prenatal cocaine exposure is associated with increased risk of miscarriage, fetal growth restriction, preterm birth, decreased birth weight and head circumference, and neurobehavioral dysfunction in neonates. No consistent pharmacological neonatal abstinence syndrome requiring treatment has been identified for cocaine (Wouldes & Lester 2019, [Ref unverified PMID 30803902]; Behnke & Smith 2013, [Ref 28]).

---

## Harm Reduction

### Contamination and Adulteration

**Levamisole:** Approximately 75% of Australian cocaine samples are adulterated with levamisole (Pope et al. 2018, [Ref 26]); US estimates range to 69–80%. Levamisole is a veterinary anthelmintic and former immunomodulatory drug withdrawn from human use due to agranulocytosis. Cocaine users exposed to levamisole-adulterated cocaine are at risk of severe neutropenia and agranulocytosis, recurrent infections, and sepsis (George et al. 2019, [Ref unverified PMID 30589731]; Khan et al. 2018, [Ref unverified PMID 29853712]). ANCA-associated vasculitis with necrotic purpura is a dermatologic presentation (Macias Alonso et al. 2021, [Ref unverified]).

**Fentanyl and synthetic opioids:** The illicit drug supply increasingly contains fentanyl as adulterant across multiple drug classes. Drug-checking services (FTIR spectroscopy, fentanyl test strips) are recommended. Unexpectedly fentanyl-containing cocaine presents overdose risk in users without opioid tolerance.

**Drug checking:** Cocaine reagent testing (Scott test/bleach test, or cobalt thiocyanate) can identify cocaine presence but not all adulterants. Point-of-care FTIR is more specific.

### Route-Specific Harm Reduction

- **Intranasal:** Use one side at a time; rinse with saline; avoid sharing straws (blood-borne virus transmission risk); CIMDL risk increases with heavy, prolonged use
- **Smoked:** Crack/free base produces most rapid addiction trajectory; pipe burns; crack lung risk
- **IV:** Greatest dependence risk; infection risk (HIV, hepatitis C); endocarditis risk
- **Oral:** Most gradual onset; lowest reinforcement; highest bioavailability at lower doses than expected due to first-pass metabolism

### Cardiovascular Considerations

Beta-blockers are **contraindicated** in cocaine intoxication due to risk of unopposed alpha-stimulation worsening coronary vasospasm. Benzodiazepines are first-line for agitation and sympathomimetic excess management. Avoid class Ia/III antiarrhythmics [Ref 3].

### Temperature

Hyperthermia is a primary mode of cocaine fatality. Physical exertion (e.g., dancing) during cocaine use substantially increases risk. Emergency cooling measures are critical in hyperthermic overdose [Ref 45].

### Medical Contraindications

Cocaine use is absolutely contraindicated with:
- Preexisting cardiac conduction disease or long QT syndrome
- Recent MI or unstable angina
- Hypertensive emergency
- History of cocaine-induced vasospasm or stroke

### No Approved Pharmacotherapy

No FDA-approved pharmacotherapy exists for cocaine use disorder (Gushken et al. 2025, [Ref 38]; Allen & Nader 2025, [Ref unverified PMID 39875301]). Cognitive-behavioral therapy remains the evidence-based standard of care. Clinical trials are testing sustained-release dexamphetamine, cannabidiol, clonidine, and rTMS.

---

## Tolerance & Dependence

### Tolerance

**Acute tachyphylaxis:** Within a single session, cocaine's euphoric effects diminish rapidly despite sustained plasma levels — this drives compulsive redosing and binge patterns. This is thought to reflect rapid desensitization of postsynaptic dopamine signaling.

**Chronic tolerance to euphoric effects:** Cocaine self-administration in rats produces tolerance to the DAT-inhibiting effects of cocaine in the nucleus accumbens core. After 60 days abstinence, tolerance appeared to recover — but a single re-infusion fully reinstated tolerance, indicating the DAT is left in a "primed" state (Siciliano et al. 2016, [Ref 25]). This is a potential mechanism for the binge episodes seen even after sustained abstinence.

**D2/D3 receptor downregulation:** Cocaine users show lower striatal D2/D3 receptors on PET compared to controls, associated with decreased activity in the orbitofrontal cortex and anterior cingulate gyrus (Volkow et al. 2011, [Ref 17]; Ashok et al. 2017, [Ref 21]). This is thought to underlie impaired inhibitory control and compulsive drug use. D3 receptors are adaptively upregulated in some brain regions (Staley & Mash 1996, [Ref 40]).

**Behavioral sensitization:** Paradoxically, while tolerance to euphoric effects develops, sensitization to locomotor, cue-reactive, and craving responses increases with repeated use — the neurobiological foundation of compulsive binge use patterns. The seed data's description of "dual process" is supported by the literature [Ref 2, Ref 17, Ref 31].

**Cross-tolerance:** Evidence supports cross-tolerance with other dopaminergic stimulants (amphetamine, methamphetamine, methylphenidate) through shared DAT downregulation and D2 receptor neuroadaptations [Ref 21].

**Epigenetic changes:** Cocaine produces BDNF dysregulation — lower serum BDNF in active cocaine users; BDNF increases during early abstinence and the magnitude of increase correlates with craving and relapse prediction (Corominas-Roso et al. 2013, [Ref 50]; Corominas-Roso et al. 2015, [Ref unverified PMID 25592977]).

### Dependence

**Psychological dependence: HIGH.** Cocaine is among the most reinforcing drugs tested in animal self-administration paradigms (Everitt & Robbins 2005, [Ref 31]; Everitt & Wolf 2002, [Ref unverified]). Animals will self-administer cocaine to the exclusion of food, water, and sleep.

**Physical dependence: LOW.** No severe physical withdrawal syndrome comparable to opioids or alcohol. Cocaine withdrawal is primarily characterized by dysphoria, fatigue, anhedonia, hypersomnia, and craving (consistent with DSM-5 cocaine withdrawal syndrome).

**Compulsive redosing: HIGH.** The short duration of euphoria (particularly via fast routes) combined with post-dose dysphoria drives rapid binge cycles.

**Incubation of craving:** A critical and clinically important phenomenon — cue-induced cocaine craving increases (rather than decreases) during abstinence over weeks to months (Gueye et al. 2019, [Ref 39]). This is associated with time-dependent increases in BDNF in the prelimbic cortex, nucleus accumbens core, and VTA [Ref 39]. Speed of cocaine delivery is a key determinant: rapid injection rats show greater incubation of craving [Ref 39].

**Habits-to-compulsions transition:** Repeated cocaine use drives a neurobiological transition from prefrontal cortical control (voluntary use) to dorsal striatal control (habitual/compulsive use) (Everitt & Robbins 2005, [Ref 31]; Kalivas & O'Brien 2008, [Ref 32]).

**1.4 million Americans** meet criteria for cocaine use disorder (Gushken et al. 2025, [Ref 38]).

---

## Interactions

### Alcohol (Cocaine + Ethanol): DANGEROUS

Concurrent cocaine and ethanol use leads to transesterification in the liver producing **cocaethylene** — a pharmacologically active cocaine analog with comparable DAT affinity, similar hepatotoxic potential via ROS generation, and longer half-life than cocaine (Dean et al. 1992, [Ref 9]; Boelsterli et al. 1993, [Ref 8]). Human controlled study demonstrates combined cocaine + alcohol is more potent and potentially more toxic than either alone (McCance-Katz et al. 1998, [Ref 33]). The combination is the most common poly-drug use pattern in cocaine users. Cocaethylene produces greater and more prolonged cardiovascular stress than cocaine alone.

**Mechanism:** Hepatic carboxylesterases + ethanol → cocaethylene. Ethanol inhibits cocaine hydrolysis to benzoylecgonine (normally a protective pathway), increasing cocaine and norcocaine concentrations [Ref 9].

### NBOMe Compounds (25I-, 25C-, 25B-, 25N-NBOMe): DANGEROUS

Classified as dangerous in the seed data. Mechanism: NBOMes are potent 5-HT2A agonists with documented hypertensive and vasoconstrictive effects. Cocaine's sympathomimetic effects (vasoconstriction, tachycardia, hypertension) combined with NBOMe-induced vasoconstriction and serotonergic hyperstimulation creates additive or synergistic cardiovascular risk. Additionally, cocaine blocks SERT, potentially amplifying serotonergic effects. No specific controlled studies on this combination were found in this research session. **FLAG: Interaction severity classified as "dangerous" in seed data; specific mechanistic publications not retrieved. Classification appears plausible based on pharmacological profiles.**

### MDMA: classification listed as "unknown" in seed data

Pharmacological reasoning suggests risk: cocaine (SERT + DAT + NET blockade) + MDMA (SERT >> DAT/NET; also serotoninergic releasing agent) produces combined serotonergic load and cardiovascular stress. Both increase body temperature. **FLAG: No controlled human study found in this session. The "unknown" classification in seed data is appropriate given literature gap, but pharmacological risk is real and should be noted in the article.**

### Tramadol: LETHAL (seed data classification)

Tramadol is a weak mu-opioid agonist and serotonin/norepinephrine reuptake inhibitor. Concurrent use with cocaine creates risks of: (1) cardiovascular interaction via combined norepinephrine potentiation; (2) possible serotonin syndrome from combined SERT inhibition. **FLAG: Specific mechanistic studies not retrieved in this session. The "lethal" classification in the seed data requires a primary source for verification. This is a safety-critical value that should be flagged.**

### MCPP and MDEA: LETHAL (seed data classification)

mCPP (meta-chlorophenylpiperazine) is a serotonin receptor agonist/releasing agent; MDEA (MDE, "Eve") is an entactogen. Combined with cocaine's serotonergic effects, these carry serotonin syndrome risk. **FLAG: Specific studies not retrieved. Safety-critical values requiring primary source verification.**

### αMT: LETHAL (seed data classification)

αMT (alpha-methyltryptamine) is a non-selective monoamine releaser and MAO inhibitor. Cocaine + MAO inhibitor is a recognized dangerous combination. **FLAG: Specific studies not retrieved.**

### Methylnaphthidate: LETHAL (seed data classification)

Methylnaphthidate is a DAT/NET inhibitor. Combined with cocaine, may produce additive cardiovascular and CNS stimulant toxicity. **FLAG: Specific studies not retrieved.**

### 5-MeO Tryptamines (5-MeO-DMT, 5-MeO-DALT, 5-MeO-DiPT, 5-MeO-MiPT): DANGEROUS

Strong 5-HT1A/2A agonists combined with cocaine's SERT/NET blockade create cardiovascular and serotonergic risk. No specific combination studies retrieved.

### Dextromethorphan: DANGEROUS

DXM is a sigma-1 receptor agonist and NMDA antagonist with mild serotonin reuptake inhibitory properties. Combined with cocaine's SERT blockade, serotonin syndrome is a theoretical risk. The "dangerous" classification is plausible.

### Rolicyclidine / PCP / Methoxetamine: DANGEROUS

Dissociatives combined with cocaine create combined cardiovascular stimulation risk. PCP alone can cause tachycardia and hypertension; cocaine's sympathomimetic effects are additive.

### CYP Enzyme Interactions

CYP3A4 inhibitors (e.g., some antifungals, macrolide antibiotics, grapefruit) could reduce norcocaine formation, potentially decreasing hepatotoxicity but increasing parent cocaine exposure. CYP3A4 inducers could increase norcocaine production. Clinical significance not well-studied.

---

## Legal Status

**United States:** Schedule II under the Controlled Substances Act (21 U.S.C. § 812). High potential for abuse; medical use retained for topical local anesthesia (ENT surgery). Prescription required (written or electronic). [Ref 48]

**United Kingdom:** Class A drug, Schedule 2 (Misuse of Drugs Act 1971). Class A is the most restrictive category. Schedule 2 permits limited medical/research use under license. Possession without prescription carries maximum 7 years imprisonment; supply up to life imprisonment.

**Canada:** Schedule I of the Controlled Drugs and Substances Act (CDSA) — the most restrictive schedule, alongside heroin and methamphetamine. No general medical license; limited research exemptions.

**Australia:** Schedule 8 (Controlled Drug) in the Poisons Standard (Standard for the Uniform Scheduling of Medicines and Poisons). Limited medical use permitted.

**European Union:** Cocaine is illegal in all EU member states, classified under the 1961 UN Single Convention. Portugal has decriminalized all drug possession for personal use (supported by treatment). Netherlands, Belgium, and Spain show relatively high use prevalence in wastewater surveillance data despite full illegality.

**International framework:** 1961 UN Single Convention on Narcotic Drugs classifies cocaine in Schedule I (high addiction risk, limited therapeutic use) and Schedule IV (most dangerous — requiring measures to prohibit all use except for medical and scientific purposes requiring a specific permit). The coca leaf is also scheduled.

**Medical use (all jurisdictions):** Cocaine 4–10% solution is approved for topical nasal/pharyngeal anesthesia in ENT and head/neck surgery. Its dual properties (local anesthetic + vasoconstrictor) remain clinically useful and unreplicated by synthetic alternatives.

---

## Clinical Trials

The following trials were identified via ClinicalTrials.gov search:

| NCT ID | Title | Status | Phase | Sponsor |
|--------|-------|--------|-------|---------|
| NCT02538744 | Complementary Combination Therapy for Cocaine Dependence | COMPLETED | Phase 1 | Baylor College of Medicine |
| NCT01986075 | Sequenced Behavioral and Medication Intervention for Cocaine Dependence | COMPLETED | Phase 1 | NY State Psychiatric Institute |
| NCT06159387 | Cannabis Extract vs Placebo for Cocaine Addicts (RCT) | UNKNOWN | Phase 4 | University of Sao Paulo General Hospital |
| NCT07313371 | Clonidine for Reducing Craving in Cocaine/Crack Use Disorder | RECRUITING | Phase 4 | University of Sao Paulo General Hospital |
| NCT05529927 | Sustained-Release Dexamphetamine for Moderate-Severe Cocaine Use Disorder | NOT YET RECRUITING | Phase 2 | Parnassia Addiction Research Centre |
| NCT02559167 | Cannabidiol and Cocaine Craving/Dependence | COMPLETED | Phase 2 | CHUM (Montreal) |
| NCT00566969 | Cocaine Withdrawal and Pharmacotherapy Response | COMPLETED | N/A | Yale University |
| NCT01639157 | Impact of Buspirone Maintenance on Reinforcing Effects of Cocaine | COMPLETED | N/A | William Stoops |
| NCT00136734 | Methylphenidate Treatment for Cocaine Abuse and ADHD | COMPLETED | Phase 1 | NY State Psychiatric Institute |

**Key finding:** No FDA-approved pharmacotherapy exists for cocaine use disorder as of 2025–2026 (Gushken et al. 2025 [Ref 38]). Active research areas include agonist substitution therapy (dexamphetamine), cannabinoids, clonidine, and neuromodulation (rTMS, NCT40336040).

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No community feedback items to evaluate.

---

## Gaps & Flags

### Safety-Critical Values Requiring Editorial Verification

1. **FLAG (SAFETY-CRITICAL): Tramadol + cocaine "lethal" interaction** — No primary source retrieved in this session. The mechanism (combined cardiovascular/NE effects, possible serotonin syndrome) is pharmacologically plausible but the "lethal" classification requires citation verification before publication.

2. **FLAG (SAFETY-CRITICAL): MCPP + cocaine "lethal" interaction** — No primary source retrieved. MCPP is a serotonergic agent; combined serotonin syndrome risk is plausible but unconfirmed by specific study.

3. **FLAG (SAFETY-CRITICAL): MDEA + cocaine "lethal" interaction** — No primary source retrieved.

4. **FLAG (SAFETY-CRITICAL): αMT + cocaine "lethal" interaction** — αMT has MAO-inhibiting properties; mechanism of lethality with cocaine is plausible but no specific study retrieved.

5. **FLAG (SAFETY-CRITICAL): Methylnaphthidate + cocaine "lethal" interaction** — No primary source retrieved.

6. **FLAG (SAFETY-CRITICAL): 2-FEA + cocaine "lethal" interaction** — No primary source retrieved.

### Interaction Severity Flags

7. **NBOMe compounds (25I-, 25C-, 25B-, 25D-, 25N-NBOMe) + cocaine: "dangerous"** — Pharmacological rationale is sound (additive vasoconstriction, cardiovascular stress) but no specific combination study was retrieved.

8. **MDMA + cocaine: "unknown"** in seed data — The pharmacological risk profile suggests this should probably be "dangerous" rather than "unknown," as both cocaine and MDMA exert combined cardiovascular and serotonergic stress. Editorial review recommended.

9. **Cannabis + cocaine: "unknown"** — There is published human laboratory data on the combination (Spronk et al. 2016 tested each separately; no combined study found). The physiological interaction is complex (cannabis is vasodilatory; cocaine vasoconstrictive). Classification warrants investigation.

### Dose Data

10. **IV heavy threshold (≥15 mg):** Controlled human studies by Johnson 2013 used 0.325–0.65 mg/kg IV (equivalent ~23–46 mg for 70 kg subject) as standard research doses. The seed data's heavy threshold of ≥15 mg may be conservative for recreational IV use, though it may capture threshold-to-heavy escalation in naive users. This warrants editorial review.

### Data Gaps

11. **SMILES string:** Not returned by PubChem API in this session. Retrievable from PubChem CID 446220.

12. **Smoked cocaine (crack) human PK studies:** Specific controlled pharmacokinetic studies for the smoked route (Javaid et al. 1978/1983 series) were not retrieved through the available API searches. Duration/onset data in the seed data are consistent with clinical descriptions but lack a direct API-verified citation in this session.

13. **Coca leaf traditional use — primary sources:** No primary anthropological/ethnobotanical studies were retrieved. Historical claim that Andean peoples have chewed coca leaves for millennia is well-established culturally but not API-verified here.

14. **No controlled cross-tolerance studies in humans:** The cross-tolerance data in the seed data (amphetamine, methamphetamine, methylphenidate) is mechanistically well-supported (shared DAT downregulation) but was not confirmed by a specific controlled human cross-tolerance study.

15. **Oral dosing timeline:** The seed data shows onset 30–40 min, come_up 40–50 min, peak 60–180 min for oral cocaine. The Coe et al. 2018 [Ref 1] study provides bioavailability data but not detailed onset/Tmax data — these ranges should be noted as estimates.

16. **Harrison Narcotics Tax Act (1914) and 1961 UN Convention scheduling** — cited as historical facts, not retrieved via primary source in this session. Standard historical record.

17. **Cocaine's effects on the developing brain / neurotoxicity in chronic users** — Limited data retrieved; neuropathological alterations in cocaine abusers documented [Ref 15] but specific neurotoxicity mechanisms less well characterized than cardiovascular toxicity.

Cocaine

Value Provenance

Dosing

insufflatedtrace →

smokedtrace →

intravenoustrace →

oraltrace →

Duration

insufflated

smoked

intravenous

oral

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

oral

intravenous

insufflated

smoked

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

Research Trail

insufflatedtrace

smokedtrace

intravenoustrace

oraltrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace